IND Number:  [ADDRESS_1220284] Number: 2016 -002639-14Regeneron Pharmaceuticals, Inc.
Clinical Study Protocol
A PHASE 3, DOUBLE-MASKED, RANDOMIZED STU DY OF THE 
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT 
INJECTION IN PATIENT S WITH MODERATELY SEVERE TO SEV ERE 
NONPROLIFERATIVE DIABETIC RETINOPATHY
Compound: Intravitreal Aflibercept Injection
Clinical Phase: 3
Protocol Number: VGFTe -OD-1411
Protocol Version : VGFTe -OD-1411 Amendment 5
Amendment 5 Date of Issue: See appended electronic signature [CONTACT_31622] 4 Date of Issue: Japan only
Amendment 3 Date of Issue: 20Oct 2016
Amendment 2 Date of Issue: 12 Feb 2016
Amendment 1 Date of Issue: 22Dec 2015
Original Date of Issue: 25 Sep 2015
Scientific/Medical Monitor:
Director, C linical Sciences, Ophthalmology
Regeneron Pharmaceuticals, Inc.
[ADDRESS_1220285]
Tarrytown, NY [ZIP_CODE]
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07[STUDY_ID_REMOVED]
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 2
CONFIDENTIALAMENDMENT HISTORY
Amendment 5
The purpose of this amendment is to change the time point for evaluation of the secondary 
endpoints from week 100 to week 52.
The secondary outcome measures include as sessment of parameters associated with the 
prevention of vision threatening complications s econdary to diabetic retinopathy, and central-
involved diabetic macular edema (DME).  Th ese secondary outcome measures were to be 
analyzed in an exploratory manner at week 52 and formally tested at week 100.  At week 24, 
these measures were assessed from a safety pers pective, and there was a remarkable separation 
between the Intravitreal Afliberc ept Injection (IAI) and sham groups.  This separation was highly 
suggestive that IAI has a profound impact on these out comes in diabetic retinopathy patients.  In 
light of these results, Regeneron feels that it is important to make these data available to the 
diabetic retinopathy community through approved labeling as soon as possible.
Change Sections Changed 
Change the timepoint for evaluation of the secondary 
endpoints from week 100 to week 52 , with additional 
exploratory analysis of the secondary endpoints at 
week 100.Clinical Study Protocol Synopsis : Endpoints,
Statistical Plan
Figure 1 Study Flow Diagram
Section 8.2 Primary and Secondary 
Variables
Section 9.1 Statistical Hypothesis
Table 4 Significance Levels for Testing 
Secondary Efficacy Endpoints
Section 9.5.2 Efficacy Analyses
Section [IP_ADDRESS] Analyses of Primary and 
Secondary Efficacy Variables
Amendment 3
The purpose of this amendment is to update exclusion criterion #16 to exclude women who are 
breastfeeding from participation in the study.
Change Sections Changed 
Exclusion updated: ‚Äú 16.Women who are breastfeeding or 
who have a positive serum hCG/urine pregnancy test at 
the screening or baseline visit ‚Äù.Section 4.2.2 Exclusion Criteria (#16)
Added EudraCT Number. Title Page
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 3
CONFIDENTIALAmendment 2
The purpose of this amendment is to incorporate the following revisions in response to feedback 
from the Food and Drug Administration (FDA) and  the Pharmaceuticals and Medical Devices 
Agency (PMDA):
xRevise the significance levels for testing of the secondary efficacy endpoints, per 
FDA feedback
xAdd a hemoglobin A1c (HbA1c) assessmen t at week 24, and fundus photography 
(FP) at week 8, per PMDA feedback
Amendment 1
The purpose of this amendment is to incorporate the following changes and clarifications 
following discussions with the FDA:
xThe primary outcome measure of the study will be the proportion of patients who 
have improved by ‚â•2 steps  from baseline in the Diabetic Retinopathy Severity Scale 
(DRSS) score at week [ADDRESS_1220286] been modified sl ightly; a few have been separated into 
2 endpoints.
xThe 2Q8 group will transition to a flexible dosing regimen based on the investigator's 
assessment of DRSS score beginning at week 56.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 4
CONFIDENTIALCLINICAL STUDY PROTOCOL SYNOPSIS 
Title A Phase 3, Double -Masked, Randomized Study of the Efficacy and Safety of 
Intravitreal Aflibercept Injection in Patien ts with Moderately Severe to Severe
Nonproliferative Diabetic Retinopathy
Site Locations Approximately 70 sites.
Objectives The primary objective of the study is to assess the efficacy of intravitreal (IVT) 
aflibercept compared to sham treatment in the improvement of moderately severe 
tosevere nonproliferative diabetic retinopathy (NPDR).
The secondary objectives of the study are:
xTo characterize the safety of IVT aflib ercept in patients with moderately 
severe to severe NPDR 
xTo determine if IVT aflibercept w ill prevent the worsening of diabetic 
retinopathy and reduce the incidence of diabetic macular edema (DME)
xTo determine the anatomic effects of  IVT aflibercept in patients with 
moderately severe to severe NPDR.
Study Design This is a phase 3, double -masked, randomized study of the ef ficacy and safety of 
IVT aflibercept for the improvement of  moderately severe to severe NPDR.
Eligible patients will be enrolled into  1 of 3 treatment groups in a 
1:1:1 randomization scheme, and will be stratified based on their Diabetic 
Retinopathy Severi ty Scale (DRSS) score (level 47 vs. level 53).  Only [ADDRESS_1220287] the following dosing 
regimens from day 1 to week 48:  1) ev ery 8 weeks (2Q8) aflibercept IVT after 5 
initial monthly doses; 2) e very 16 weeks (2Q16) aflibercept IVT after 3 initial 
monthly doses and 1 Q8 interval; and 3) sham treatment.  In year 2 (beginning at week 56), the 2Q8 group will be treated with a flexible treatment regime
n.
The primary outcome measure of the study is the proportion of patients who have improved by ‚â•2 steps from baseline on the DRSS in the 
combined 2Q8 and 2Q16 
group s at week 24, and in each group separately at week 52.
Patients will be evaluated for efficacy (bes t corrected visual acuity [BCVA] using 
the 4-meter Early Treatment Diabetic Retinopathy Study [ETDRS] protocol, 
spectral domain o ptical coherence tomography [SD- OCT], and fluorescein 
angiography [FA]/fundus photography [FP]) and for ocular and systemic safety 
(including ophthalmic exams, visual field testing, and laboratory assessments) through week 100.
Patients who develop PDR, anterior segment neovascularization
(ASNV) , or DME 
in the study eye will qualify for rescue treatm ent.  If treatment is given, patient data 
will be censored for the primary analysis.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 5
CONFIDENTIALIntravitreal aflibercept (2 mg) will be ma de available for patients who have central-
involved DME (CI-DME), PDR or ASNV in the fellow eye at screening (beginning 
on day 1), or are diagnosed during the trial.  
Standard of care treatment (eg, PRP ) will also be allowed for patients developi[INVESTIGATOR_873760].
Study Duration The study duration is 103 weeks, including the screening period.
Population
Sample Size:  Approximately 360 patients will be enro lled, and with a target enrollment of 
approximately 1 20 patients in each treatment group (1:1:1 ratio).
Target Population: The patient population will include men or women with type [ADDRESS_1220288] (without DME threatening 
the center of the macula), in whom PRP can be safely deferred for at least [ADDRESS_1220289] equivalen t scores, 
factors such as ocular dominance and patient preference should be considered in 
making the selection.
Treatments
Study Drug
Dose/Route/Schedu
le:The investigational product is intravitreal aflibercept injection (IAI), and will be 
administere d to the patients by [CONTACT_576499].
Study Eye
Patients will be randomly assigned to 1 o f 3 treatment groups in a 1:1:1 ratio:
x2Q8:  aflibercept 2 mg Q8 to week 48 (after 5 initial monthly doses),
followed by a flexible treatment regimen with aflibercept 2 mg to week 96
x2Q16:  aflibercept 2 mg Q16 to week 96 (after 3 initial monthly doses and 1 
Q8 interval)
xSham:  sham injections every 4 weeks (Q4) to week 16, followed by [CONTACT_873767] Q8 to week 96
To preserve the masking, sham injections will be performe d for the 2Q8 and 2Q16 
group sat treatment visits in which patients  do not receive an active injection 
through week 96, and at all treatment visits for the sham group from baseline to 
week 96.  Masking will be maintained to the end of the study (week 100).
Endpoints
Primary: The primary outcome measure of the study is the proportion of patients who have improved by ‚â•2 steps from bas
eline in the DRSS score at week 24 in the combined 
2Q8 and 2Q16 groups, and at week 52 for each group separately.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 6
CONFIDENTIALSecondary: The secondary outcome measures will be tested at week 52 and are as follows:
xProportion of patients developi[INVESTIGATOR_007] a vision-threatening complication due to 
diabetic retinopathy
Vision-threatening complications are defined as composite outcome of 
PDR (inclusive of patients who have vitreous hemorrhage or tractional 
retinal detachment believed to be due to PDR) and ASNV
oNote:  ASNV is defined as neovascularization of the iris (at least 2 
cumulative clock hours), and/or definitive neovascularization of 
the iridocorneal angle
xProportion of patients who develop CI-DME
xTime to development of a vision-threatening complication
xTime to development of CI-DME
xProportion of patients who receive PRP, inclusive of patients undergoing 
vitrectomy with endolaser 
xArea under the curve (AUC) for change in BCVA from baseline
These outcome measures will also be tested at week 100in an exploratory manner 
for all 3 treatment groups.
Procedures and 
AssessmentsEfficacy and safety ocular procedures will include BCVA (ETDRS) and refraction, 
intraocular pressure (IOP), slit lamp examination ,gonioscopy, indirect 
ophthalmoscopy, SD -OCT, FA/FP, and visual field testing (study eye).
Overall safety will be assessed by [CONTACT_812000] -emergent adverse events 
(TEAEs), physical examinations, electroc ardiograms (ECGs), vital signs, and 
clinical safety laboratory tests (hematology, blood chemistry, hemoglobin A1c [HbA1c], and urinalysis) at pr especified time points.  
Statistical Plan The primary efficacy variable is the proportion of patients with a ‚â•2 -step 
improvement from baseline in DRSS score in the study eye at week 24 in the 
combined 2Q8 and 2Q16 groups, and at week 52 for the 2Q8 and 2Q16 groups
separately .  Statistical testing of week 24 and week 52 will be conducted to 
demonstrate the superiority of the aflibercept  groups (combined, 2Q8, and 2Q16) to 
the sham group, respectively.
The primary efficacy variable analysis w ill be conducted on the full analysis set 
(FAS) population.  The primary analysis is a statistical evaluation of superiority of 
3comparisons (combined aflibercept vs. sham at week 24, aflibercept 2Q8 vs.
sham at week 52, and aflibercept 2Q16 v s. sham at week 52) in respect to the 
primary eff icacy variable. The statistical analysis will be performed using the 
Cochran-Mantel- Haenszel method, stratified by [CONTACT_873768] (level 47 vs. 
level 53).  Missing or n ongradable post- baseline values will be imputed using the 
last observation carried forward (LOCF) procedure. For any patient who receives 
rescue treatment, the measurements after re scue is given will be imputed using the 
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220290] -baseline observations are missing or nongradable.
Aflibercept treatment will be considered to  be superior to sham if the estimated 
aflibercept group (combined, aflibercept 2Q 8, or aflibercept 2Q16) is greater than 
the sham group, and the p -value is less than or equal to or statistically significant at 
a 1.67% level.
A hierarchical testing procedure will be performed for each dose group to compare 
the secondary efficacy variables between the respective aflibercept group and the 
sham group at week 52.
For a sensitivity analysis, the primary efficacy analysis will also be performed 
using all observed measurements (regardless of whether rescue treatment was 
given), and only true missing values will be imputed using the LOCF procedure.  
Baseline values will be carried forward if all post-baseline observations are missing
or nongradeable .
Safety Variabl es
Safety variables will be summarized on the safety analysis set (SAF) through week 
[ADDRESS_1220291] results will be summarized by 
[CONTACT_50475]. 
Sample Size
Anticipating approximately 4 1% of patients with a ‚â•2 -step improvement from 
baseline in DRSS score in either the 2Q8 or  2Q16 groups versus 17% in the sham 
group, [ADDRESS_1220292] a difference with a power of 90% for rejec
ting the null hypothesis at a 2-sided 1.67% (5%/3 ) significance level.  
A sample size of [ADDRESS_1220293] 90% power to detect a 
difference between the combined aflibercept group and sham group at week 24, if a38%
response rate is assumed in the combined aflibercept group.  To account for 
about a 15% dropout rate, 120 patients  per group will be enrolled.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220294] OF ABBREVIATIONS AND DEFINITIONS OF TERMS................................................13  
1. INTRODUCTION AND RATIONALE.....................................................................15  
1.1. Introduction.................................................................................................................15  
1.2. Rationale.....................................................................................................................1 6 
1.2.1.  Rationale for Study Design.........................................................................................16  
1.2.2.  Rationale for Dose Selection ......................................................................................16  
2. STUDY OBJECTIVES ..............................................................................................17  
2.1. Primary Objective.......................................................................................................17  
2.2. Secondary Objectives .................................................................................................17  
3. STUDY DESIGN .......................................................................................................17  
3.1. Study Description and Duration .................................................................................17  
3.2. Planned Interim Analysis............................................................................................18  
3.3. Study Committees.......................................................................................................18  
3.3.1.  Safety Monitoring Team.............................................................................................18  
3.3.2.  Other Safety Committee .............................................................................................18  
4. SELECTION, WITHDRAWAL, AND REPLACEMENT OF PATIENTS..............19  
4.1. Number of Patients Planned .......................................................................................19  
4.2. Study Population.........................................................................................................19  
4.2.1.  Inclusion Criteria ........................................................................................................19  
4.2.2.  Exclusion Criteria .......................................................................................................19  
4.3. Premature Withdrawal from the Study.......................................................................21  
4.4. Replacement of Patients .............................................................................................21  
5. STUDY TREATMENTS............................................................................................21  
5.1. Investigational and Reference Treatments..................................................................21  
5.2. Rescue Treatment in the Study Eye............................................................................22  
5.3. Flexible Treatment in the 2Q8 Group in the Study Eye .............................................22  
5.4. Dose Modification and Study Drug Discontinuation Rules .......................................22  
5.4.1.  Dose Modification ......................................................................................................22  
5.4.2.  Study Drug Discontinuation .......................................................................................22  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 9
CONFIDENTIAL5.5. Method of Treatment Assignment ..............................................................................23  
5.5.1.  Masking ......................................................................................................................23  
5.5.2.  Emergency Unmasking...............................................................................................25  
5.6. Treatment Logistics and Accountability.....................................................................25  
5.6.1.  Packaging, Labeling, and Storage ..............................................................................25  
5.6.2.  Supply and Disposition of Treatments .......................................................................25  
5.6.3.  Treatment Accountability ...........................................................................................26  
5.6.4.  Treatment Compliance................................................................................................26  
5.7. Concomitant Medications and Procedures .................................................................26  
5.7.1.  Prohibited Medications and Procedures .....................................................................26  
5.7.2.  Permitted Medications and Procedures ......................................................................27  
6. STUDY SCHEDULE OF EVENTS AND VISIT DESCRIPTIONS.........................27  
6.1. Schedule of Events .....................................................................................................27  
6.2. Study Visit Descriptions .............................................................................................33  
6.2.1.  Early Termination Visit ..............................................................................................33  
6.2.2.  Unscheduled Visits .....................................................................................................33  
6.3. Study Procedures ........................................................................................................33  
6.3.1.  Procedures Performed Only at the Screening/Baseline Visit .....................................33  
6.3.2.  Ocular Procedures (Efficacy and Safety) ...................................................................33  
[IP_ADDRESS].  Best Corrected Visual Acuity .....................................................................................33  
[IP_ADDRESS].  Intraocular Pressure ....................................................................................................33  
[IP_ADDRESS].  Slit Lamp Examination ...............................................................................................33  
[IP_ADDRESS].  Gonioscopy.................................................................................................................34  
[IP_ADDRESS].  Indirect Ophthalmoscopy............................................................................................34  
[IP_ADDRESS].  Fundus Photography/Fluorescein Angiography .........................................................34  
[IP_ADDRESS].  Spectral Domain Optical Coherence Tomography.....................................................34  
[IP_ADDRESS].  Visual Field Testing....................................................................................................35  
6.3.3.  Safety Procedures (Non-Ocular).................................................................................35  
[IP_ADDRESS].  Vital Signs ..................................................................................................................35  
[IP_ADDRESS].  Physical Examination .................................................................................................35  
[IP_ADDRESS].  Electrocardiogram.......................................................................................................35  
[IP_ADDRESS].  Laboratory Testing......................................................................................................35  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 10
CONFIDENTIAL6.3.4.  Anti-Drug Antibody Procedures ................................ ................................ ................. 37 
[IP_ADDRESS].  Anti-Drug Antibody Measurements and Samples ................................ ...................... 37 
  
7. SAFETY DEFINITIONS, REPORTING, AND MONIT ORING ............................. 37 
7.1. Definitions ................................ ................................ ................................ .................. 37 
7.1.1.  Adverse Event ................................ ................................ ................................ ............. 37 
7.1.2.  Serious Adverse Event ................................ ................................ ................................ 38 
7.2. Recording and Reporting Adverse Events ................................ ................................ ..38 
7.2.1.  Adverse Events ................................ ................................ ................................ ........... 38 
7.2.2.  Serious Adverse Events ................................ ................................ .............................. 39 
7.2.3.  Other Events that Require Accelerated Reporting ................................ ...................... 39 
7.2.4.  Reporting Adverse Events Leading to Withdrawal from the Study ........................... 40 
7.2.5.  Abnormal Laboratory, Vital Signs, or Electrocardiogram Results ............................. 40 
7.2.6.  Follow -up................................ ................................ ................................ .................... 40 
7.3. Evaluation of Severity and Causality ................................ ................................ ......... 40 
7.3.1.  Evaluation of Severity ................................ ................................ ................................ 40 
7.3.2.  Evaluation of Cau sality ................................ ................................ ............................... 41 
7.4. Safety Monitoring ................................ ................................ ................................ .......41 
7.5. Investigator Alert Notification ................................ ................................ .................... 42 
8. STUDY VARIABLES ................................ ................................ ................................ 42 
8.1. Demographic and Baseli ne Characteristics ................................ ................................ 42 
8.2. Primary and Secondary Variables ................................ ................................ .............. 42 
8.3. Additional Variables ................................ ................................ ................................ ...43 
9. STATISTICAL PLAN ................................ ................................ ................................ 43 
9.1. Statistical Hypothesis ................................ ................................ ................................ ..43 
9.2. Justification of Sample Size ................................ ................................ ........................ 44 
9.3. Analysis Sets ................................ ................................ ................................ ............... 45 
9.3.1.  Efficacy Analysis Sets ................................ ................................ ................................ 45 
9.3.2.  Safety Analysis Set ................................ ................................ ................................ .....45 
9.4. Patient Disposition ................................ ................................ ................................ ......45 
9.5. Statistical Methods ................................ ................................ ................................ ......45 
9.5.1.  Demography and Baseli ne Characteristics ................................ ................................ .46 
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 11
CONFIDENTIAL9.5.2.  Efficacy Analyses .......................................................................................................46  
[IP_ADDRESS].  Analyses of Primary and Secondary Efficacy Variables............................................46  
[IP_ADDRESS].  Analyses of Additional Efficacy Variables ................................................................48  
9.5.3.  Safety Analysis ...........................................................................................................49  
[IP_ADDRESS].  Adverse Events ...........................................................................................................49  
[IP_ADDRESS].  Ocular Safety ..............................................................................................................50  
[IP_ADDRESS].  Other Safety................................................................................................................50  
[IP_ADDRESS].  Treatment Exposure....................................................................................................50  
[IP_ADDRESS].  Treatment Compliance................................................................................................[ADDRESS_1220295].........................................................................................55  
14. PROTOCOL AMENDMENTS ..................................................................................55  
15. PREMATURE TERMINATION OF THE STUDY OR CLOSE-OUT OF A 
SITE........................................................................................................................... .55 
15.1.  Premature Termination of the Study...........................................................................55  
15.2.  Close-out of a Site ......................................................................................................55  
16. STUDY DOCUMENTATION...................................................................................56  
16.1.  Certification of Accuracy of Data...............................................................................56  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 12
CONFIDENTIAL16.2.  Retention of Records ..................................................................................................56  
17. CONFIDENTIALITY ................................................................................................56  
18. FINANCING AND INSURANCE.............................................................................57  
19. PUBLICATION POLICY ..........................................................................................57  
20. REFERENCES ...........................................................................................................58  
21. INVESTIGATOR‚ÄôS AGREE MENT..........................................................................59  
APPENDIX 1.  OPTICAL COHERENCE TOMOGRAPHY - ANGIOGRAPHY 
SUB-STUDY..............................................................................................................60  
APPENDIX 2.  FACTORS TO CONSIDER IN ASSESSING THE RELATIONSHIP 
OF ADVERSE EVENTS TO STUDY DRUG OR INJECTION 
PROCEDURE.............................................................................................................61  
SIGNATURE [CONTACT_11715] ‚ÄôS RESPONSIBLE OFFIC ERS .....................................................[ADDRESS_1220296] OF TABLES
Table 1:  Responsibilities of the Masked and Unmasked Personnel .........................................24  
Table 2:  Schedule of Events ‚ÄìYear 1.......................................................................................28  
Table 3:  Schedule of Events ‚ÄìYear 2.......................................................................................31  
Table 4:  Significance Levels for Testing Secondary Efficacy Endpoints ................................[ADDRESS_1220297] OF FIGURES
Figure 1:  Study Flow Diagram...................................................................................................[ADDRESS_1220298] OF APPENDICES
Appendix 1.  Optical Coherence tomography - Angiography Sub-study ....................................60  
Appendix 2.  Factors to Consider in Assessing the Relationship of Adverse Events to 
Study Drug or Injection Procedure .............................................................................61  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220299] corrected visual acuity
BUN Blood urea nitrogen
CI-DME Central-involved DME
CPK Creatine phosphokinase
CRF Case report form (electronic or paper)
DME Diabetic macular edema
DRSS Diabetic Retinopathy Severity Scale
ECG Electrocardiogram
EDC Electronic data capture
ETDRS Early Treatment Diabetic Retinopathy Study
FA Fluorescein angiography
FAS Full analysis set
FP Fundus photography
GCP Good Clinical Practice
HbA1c Hemoglobin A1c
IAI Intravitreal aflibercept injection
ICF Informed consent form
ICH International Conference on Harmonisation
IRB Institutional Review Board
IOP Intraocular pressure
IVT Intravitreal
IVRS Interactive voice response system
IWRS Interactive web response system
LDH Lactate dehydrogenase
LOCF Last observation carried forward
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220300] Spectral Domain Optical Coherence Tomography
SMT Safety monitoring team
SOC System organ class
TEAE Treatment-emergent adverse event
VA Visual acuity
VEGF Vascular endothelial growth factor
WBC White blood cell
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 15
CONFIDENTIAL1. INTRODUCTION AND RATIONALE
1.1. Introduction
Diabetes mellitus and its complications are a worl dwide health epi[INVESTIGATOR_873761].  In 2013, the World Health Organizati on estimated that 347 million people had diabetes 
and this number has been projected to increase to 366 million by 2030 and potentially more if 
rates of obesity continue to increase ( Wild 2004 ).  Despi[INVESTIGATOR_873762], morbidity and mort ality as a consequence of diabetes, including 
diabetic retinopathy, are expected to rise.  Di abetic retinopathy is microvascular damage to the 
blood vessels in the retina, and it can progress to  vision-threatening stages including proliferative 
diabetic retinopathy (PDR), where new vessels that  are susceptible to hemorrhage grow initially 
from the retina and/or optic disc and extend be yond the internal limiting membrane, and diabetic 
macular edema (DME), where fluid accumulates disrupting the macular architecture and 
function.  Although there are treatments for DME (eg, anti-vascular endothelial growth factor 
[VEGF] agents), there is a significant unmet medical need for the treatment of diabetic 
retinopathy. More advanced retinopathy (prolif erative) is often treated with panretinal 
photocoagulation (PRP).  Although PRP may stop the progression of a proliferative disease, it is 
inherently destructive to the reti na and, therefore, likely to cause  visual symptoms such as visual 
field defects, reduced contrast sensitivity, and impaired night and color vision, and can also lead 
to exacerbation of macular edema ( Bressler 2011 ). There is currently no treatment for 
nonproliferative diabetic retinopathy (NPDR), and patients are observed until disease progresses 
sufficiently to warrant PRP.
Intravitreal (IVT) anti-VEGF therapy is currentl y the standard of care tr eatment for DME, and it 
has proven to be generally safe and effective in patients with DME.  In the phase 3 VISTA and 
VIVID studies of EYLEA¬Æ(aflibercept, known in the scientific literature and in clinical studies 
as VEGF Trap-Eye or intravitreal aflibercept injection [IAI]), patients treated with either 
aflibercept 2 mg every 4 weeks (2Q4) or aflibercept 2 mg every 8 weeks (2Q8) (following 
5 initial monthly doses) regimens gained 11.[ADDRESS_1220301] corrected 
visual acuity (BCVA) at week 52 (data on file).  Similar visual acuity (VA) gains were seen in 
the RISE and RIDE studies of 0.3 and 0.5 mg Lucentis given monthly ( Brown 2013 ).
In addition to the effect on vision, improvements in diabetic retinopathy as measured by [CONTACT_873769] (E TDRS) Diabetic Retinopathy Severity Scale 
(DRSS) were demonstrated in studies of EY LEA and Lucentis.  In the VISTA and VIVID 
studies, the proportion of patients showing a ‚â•2 -step improvement in DRSS at week 52 for the 
2Q4 and 2Q8 groups was 33.8% and 29.1% (VISTA) and 33.3% and 27.7% (VIVID), 
respectively ( Korobelnik 2014 ).  In order to confirm that these results would be consistent for a 
population with moderately severe to severe NPDR at baseline, a subgroup analysis was 
performed in patients with a ba seline DRSS score of level 47 or 53.  In this subgroup, as with the 
entire population, consistently more patients in the aflibercep t groups had a ‚â•2 -step improvement 
in DRSS (2Q4 = 49.6%, 2Q8 = 43.9%), as compared to  the laser group (16.7%) (data on file).  It 
is also worth noting that the proportion of patients with ‚â•2 -step improvement in DRSS both in 
the subgroup and the overall population at week 52 was similar at the earlier time point of 
week 24.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220302] in 
patients without DME, leaving patients at risk  for the development of DME and/or PDR.  Based 
on the evidence from the VISTA and VIVID studies in patients with DME showing that EYLEA (in addition to treating macular edema) also improves the underlying diabetic retinopathy, we 
propose to investigate EYLEA in patients with  moderately severe to severe NPDR who do not 
have DME by [CONTACT_873770] [ADDRESS_1220303].
Additional background information on the study drug can be foun d in the Investigator‚Äôs 
Brochure.
1.2. Rationale
1.2.1. Rationale for Study Design 
Patients with severe NPDR may have 20/20 vi sion and therefore experience no symptoms of 
their advancing disease.  Howe ver, profound vision loss can occur acu tely if the fragile, leaky 
vessels develop and either bleed into the vitr eous cavity or cause retinal traction and/or 
detachment ( Bressler 2011 ).  Therefore, slowing or haltin g the worsening of disease will 
minimize or completely avert these severe, often  irreversible, effects on vision in a patient
population for which there are no approved, or generally accepted, therapi[INVESTIGATOR_014].
The most comprehensive grading scale that has been developed for diabetic retinopathy was 
derived from the ETDRS.  This was a landm ark study that established the value of laser 
photocoagulation in managing diabetic retinopathy.  From this study, a systematic grading scale, 
the DRSS, was derived to predict progression from NPDR to PDR.
Based on the evidence from the VISTA and VIVID studies showing that aflibercept, in addition 
to treating macular edema, also improves the underl ying diabetic retinopathy in patients with 
severe NPDR, this study is designed to assess th e superiority of aflibercept when compared to 
sham in treating patients with moderately seve re to severe NPDR, by [CONTACT_873771] [ADDRESS_1220304] 
concurrent DME are unlikely to be experiencing vi sion loss, a longer interval between physician 
visits and injections would be preferable.  Theref ore, a dosing regimen with a longer interval will 
be tested (aflibercept 2 mg every 16 weeks [2Q16]) in the current study, along with the 2Q8 
regimen.
1.2.2. Rationale for Dose Selection
The 2 mg dose of aflibercept is the same as the currently marketed dose of EYLEA and was used 
in the phase 3 DME studies, where improvemen t in underlying diabetic retinopathy was 
demonstrated.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220305].
2.2. Secondary Objectives
The secondary objectives of the study are:
xTo characterize the safety of IVT aflibercept in patients with moderately severe to 
severe NPDR 
xTo determine if IVT aflibercept will pre vent the worsening of diabetic retinopathy 
and reduce the incidence of DME
xTo determine the anatomic effects of IVT af libercept in patients with moderately 
severe to severe NPDR
3. STUDY DESIGN
3.1. Study Description and Duration
This is a phase 3, double-masked, randomized study of the efficacy and safety of IVT aflibercept 
for the improvement of moderately severe to severe NPDR.
After providing informed consent, pa tients will be assessed for study eligibility at the screening 
visit, up to 3 weeks before day 1/baseline.  At the day 1/baseline visit, patients will undergo 
safety assessments prior to receiving the first dose of study drug.
Eligible patients will be enrolled into 1 of 3 treatment groups in a 1: 1:1 randomization scheme, 
and will be stratified based on their DRSS scor e (level 47 vs. level 53). Only [ADDRESS_1220306] the following dosing regimens from 
day 1 to week 48: 1) 2Q8 aflibercept IVT after 5 initial monthly doses; 2) 2Q16 aflibercept IVT 
after 3 initial monthly doses and 1 8-week in terval; and 3) sham treatment (see section 5.1). In 
year 2 (beginning at week 56), the 2Q8 group will be treated with a flexible treatment regimen
(see section 5.3).
The primary outcome measure of the study is the proportion of patients who have improved by 
‚â•2 steps from baseline on the DRSS in the combined  2Q8 and 2Q16 groups at week 24, and in 
each group separately at week 52.  Patients will be evaluated for efficacy (BCVA using the 
4-meter ETDRS protocol, spectr al domain optical coherence tomography [SD-OCT], and 
fluorescein angiography [FA]/fundus photography [FP]) and for ocular and systemic safety 
(including ophthalmic exams, visual field testin g, and laboratory assessments) through week 100 
(Figure 1 ).
Patients who develop PDR, anterior segment ne ovascularization (ASNV), or DME will qualify 
for rescue treatment (see section 5.2).  If treatment is given, patien t data will be censored for the 
primary analysis.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 18
CONFIDENTIALFigure 1: Study Flow Diagram
Screening Treatment
(Day ‚Äì21) (Day ‚Äì1) (Day 1) Week 24 Week 52 Week 100
Visit 1 Baseline/Visit 2 Primary Outcome
Measure (2Q8 & 2Q16 
combined)
Visit 7Primary (2Q8 & 
2Q16 separately)
and Secondary 
Outcome Measures
Visit 11End of Study
Visit 18
3.2. Planned Interim Analysis
No formal interim analysis is planned.
3.3. Study Committees 
3.3.1. Safety Monitoring Team
A safety monitoring team (SMT) at Regeneron will  meet at scheduled times during the study to 
review masked safety data.  These data may include, but are not limited to:
xTreatment-emergent adverse events (TEAEs) th at result in an early study withdrawal
xSerious adverse events (SAEs)
xFatal events
xIdentified and potential risks for IVT aflibercept
Appropriate action, if needed, will be taken ba sed upon these reviews and in consultation with 
the medical monitor.
3.3.2. Other Safety Committee
Potential arterial thrombotic events will be ev aluated by a masked adjudication committee 
according to criteria formerly appl ied and published by [CONTACT_496145]- Platelet Trialists‚Äô Collaboration 
prior to database unmasking ( Antithrombotic Trialists' Collaboration 1994; 
Antithrombotic Trialists' Collaboration 2002 ).  An arterial thrombotic event is defined as a 
nonfatal myocardial infarction, nonfatal ischemic stroke, nonfatal hemorrhagic stroke, or death resulting from vascular or unknown causes.  Additi onal details regarding data to be collected can 
be found in the study procedure manual.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220307] (without DM E threatening the center of the macula), in 
whom PRP can be safely deferred for at least [ADDRESS_1220308] meet the following criteria at screenin g and at day 1 to be eligible for inclusion in 
the study:
1. Men or wome n ‚â•[ADDRESS_1220309] (DRSS levels 47 or 53 ), confirmed by [CONTACT_73475], 
in whom PRP can be safely deferred for at least 6 months per the investigator
2. BCVA ETDRS letter score in the study eye of ‚â•69 letters (approximate Snellen 
equivalent of 20/40 or better)
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide signed informed consent
4.2.2. Exclusion Criteria
A patient who meets any of the following criteria at either the screening visit or at day 1 will be 
excluded from the study:
1. Presence of DME threatening the center of the macula (within 1,000 microns of the 
foveal center) in the study eye
2. Evidence of retinal neovascularization on clinical examination or FA
3. Any prior focal or grid laser photocoagulation (within 1,000 microns of the foveal center) 
or any prior PRP in the study eye
4. Any prior systemic anti-VEGF treatment or IVT anti-VEGF treatment in the study eye
5. Any prior intraocular steroid injection in the study eye
6. History of vitreoretinal surgery in the study eye
7.Intraocular pressure (IOP) ‚â•25 mm Hg in the study eye
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 20
CONFIDENTIAL8. Evidence of active infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
9. Any intraocular inflammation or infection in either eye within 3 months of the screening 
visit
10. Current ASNV, vitreous hemorrhage, or trac tional retinal detachment visible at the 
screening assessments in the study eye
11. Ocular media of insufficient quality to obtain fundus and optical coherence tomography 
(OCT) images in the study eye
12. Hemoglobin A1c (HbA1c) >12%, or if HbA1c is ‚â§12%, diabetes mellitus is uncontrolled
in the opi[INVESTIGATOR_871]
13. Uncontrolled blood pressure (defined as systolic >160 mm Hg or diastolic >95 mm Hg 
while patient is sitting)
14. History of cerebrovascular accident or myocardial infarction within [ADDRESS_1220310] a positive serum hCG/urine pregnancy test at 
the screening or baseline visit
17. Any concurrent ocular condition in the study eye which, in the opi[INVESTIGATOR_1070], could either increase the risk to the patient beyond what is to be expected 
from standard procedures of IVT injections, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety
18. History of other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that 
contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications
19. Participation as a patient in any interventional clinical study within the 12 weeks prior to 
day 1 of the study
20. Sexually active men* or women of childbearing potential** who are unwilling to 
practice adequate contraception prior to the initial dose/start of the first treatment, during the study, and for at least [ADDRESS_1220311] dose.  Adequate contraceptive measures 
include stable use of oral contraceptiv es or other prescription pharmaceutical 
contraceptives for 2 or more menstrual cycles  prior to screening; intrauterine device; 
bilateral tubal ligation; vase ctomy; condom plus contraceptive sponge, foam, or jelly, or 
diaphragm plus contraceptive sponge, foam, or jelly.
* Contraception is not required for men with documented vasectomy.
** Postmenopausal women must be amenorrheic for  at least 12 months in order not to be 
considered of childbearing potential.  Preg nancy testing and contraception are not 
required for women with documented hysterectomy or tubal ligation.
21. Patients who are on systemic anti-VEGF treatment (ie, bevacizumab, ziv-aflibercept) for 
oncology treatment (if a patient requires systemic anti-VEGF treatment during the study, 
the patient will be withdrawn)
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220312] the right to w ithdraw a patient from the study in the event of 
an intercurrent illness, adverse event (AE), tr eatment failure, protocol violation, cure, and for 
administrative, or other reasons .  An excessive rate of withdrawals would render the study 
uninterpretable; therefore, unnecessary withdrawal of patients should be avoided.
Patients who withdraw prematurely from the study will be asked to complete study assessments 
per section 6.2.[ADDRESS_1220313] is IAI, which will be  supplied in sterile, sealed, 3 mL, single-use 
vials, each with a ‚Äúwithdrawable‚Äù volume of approximately 50 ŒºL (0.05 mL) at a concentration 
of 40 mg/mL.
The injection volume will be 50 ŒºL (0.05 mL) and will be administer ed to the patients by [CONTACT_801525].  Only 1 eye will be selected as the study eye.
Study Eye
Patients will be randomly assigned to 1 of 3 treatment groups in a 1:1:1 ratio:
x2Q8: aflibercept 2 mg Q8 to week 48 (after 5 initial monthly doses), followed by a 
flexible treatment regimen w ith aflibercept 2 mg to week 96
x2Q16: aflibercept 2 mg Q16 to week 96 (after 3 initial monthly doses and 1 8-week 
interval)
xSham: sham injections Q4 to week 16, followed by [CONTACT_873772] Q8 to week 96
Masking will be maintained to the end of the stud y (week 100).  To preserve the masking, sham 
injections will be performed for the 2Q8 and 2Q16 groups at treatment visits in which patients do 
not receive an active injection through week 96, and at all treatment visits for the sham group 
from baseline to week 96.  Instructions on dose preparation are provided in the pharmacy 
manual.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220314], ASNV, or central-i nvolved DME (CI-DME) in the study eye may be 
treated, if deemed appropriate by [CONTACT_873773].  For any of these complications, an FP 
must be performed before rescue treatment is given.
Patients who develop CI-DME may re ceive IVT aflibercept (refer to EYLEA USPI 2015 ) or 
laser photocoagulation, and will no longer receive their randomized treatment.  Rescue treatment 
may be given by [CONTACT_873774].
Patients who develop PDR and/or ASNV may recei ve PRP or vitrectomy with endolaser, if 
necessary, but will remain on their randomized  treatment schedule. Panretinal photocoagulation 
or surgical intervention may be performed by  [CONTACT_873775]. In 
addition, [ADDRESS_1220315] is given, pa tient data will be censored from the time of 
treatment for the primary analysis.
5.3. Flexible Treatment in the 2Q8 Group in the Study Eye
Beginning at week 56, patients randomized to the 2Q8 group will receive aflibercept using a 
flexible treatment regimen.  An injection will be given at each visit unless a patient has reached 
Level 35 or better (mild NPDR) on the DRSS (as determined by [CONTACT_286823]), at 
which point treatment will be deferred (and a sh am injection given). Level [ADDRESS_1220316] exudates, cotton wool spots, and/or mild 
retinal hemorrhages (less than present in ET DRS standard photograph 2a in up to 3 quadrants 
[see also study procedure manua l]). The determination whether Level 35 or better has been 
reached will be assessed by [CONTACT_873776].
To maintain masking, all treatment groups will be  assessed (using FP) for flexible treatment 
criteria from week [ADDRESS_1220317] udy drug and who do not withdraw from the study 
will be asked to return to the clinic for all remaining study visits per the visit schedule.
Patients who opt to withdraw from the study wi ll be asked to complete study assessments, per 
section 6.2.1 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 23
CONFIDENTIAL5.5. Method of Treatment Assignment
Approximately 360 patients will be randomized in a 1:1:1 ratio to receive either aflibercept 2Q8, 
aflibercept 2Q16, or sham according to a ce ntral randomization scheme provided by [CONTACT_50445] (IVRS)/interactive web response system (IWRS) to the designated study pharmacist (or qualified design ee).  Randomization will be stratified according 
to the patient‚Äôs DRSS level (level 47 vs. level 53 at the scree ning visit).
5.5.1. Masking
To preserve the masking, sham injections will  be performed for the 2Q8 and 2Q16 groups at
treatment visits in which patients do not receiv e an active injection through week 96; sham 
injections will be performed at all treatment visits for the sham group from baseline to week 96. 
Weeks 52 and 100 are nontreatment visits.
A masked physician will be assigned to do the fo llowing:  1) assess AEs, and 2) perform the 
masked assessment of efficacy.  A separate, unmaske d physician will administer treatment in the 
study eye (ie, perform study drug injection or sham injection) ( Table 1 ).
The unmasked physician or designee will not have  any role in the study beyond the receipt, 
tracking, preparation, destruction, administration of study drug, and assessing safety during the 
observation period following study drug administ ration. The masked physician will determine if 
a patient has developed DME, ASNV, or PDR in th e study eye, and will be responsible for 
recommending treatment, which will be admini stered by [CONTACT_496161]. Once it has 
been determined that a patient has progressed to DME, ASNV, or PDR, treatment may be given by [CONTACT_873775].  Beginning at week 56, the masked physician will 
assess whether a patient has a DRSS Level [ADDRESS_1220318] be 
maintained as new personnel are added to the study team.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 24
CONFIDENTIALTable 1: Responsibilities of the Masked and Unmasked Personnel
Masked or Unmasked Personnel
xPerforms all screening procedures up until randomization
xAssesses inclusion/exclusion criteria
xObtains medical/ophthalmic history
xObtains informed consent
xCollects samples for laboratory testing and antibody sampling 
xPerforms electrocardiograms (ECGs) and transfers to reading center
xAdministers rescue treatment once the need for re scue has been determined by [CONTACT_496155] (physician only)
Masked Personnel
xDetermines if a patient has developed DME, ASNV, or PDR in the study eye and 
recommends treatment (physician only)
xAssesses AEs, including severity and relationship 
xAssesses efficacy
xPerforms ophthalmic examinations, including I OP, at all study visits (except post-dose 
examinations immediately after treatment)
xEvaluates all safety, including review of images for safety concerns (except those 
immediately after IVT injection) 
xMay perform fellow eye injections at any unsch eduled visits where only the fellow eye is 
treated
xTests refraction and BCVA (no exceptions will be granted)
xPerforms Humphrey Visual Field test
xPerforms and assesses OCT, FP, and FA images and transfers them to reading centers
xAssesses need for flexible treatment during year 2
Unmasked Personnel
xCoordinates randomization 
xPerforms receipt and accountability of study drug
xPerforms study drug (IAI) or sham injection (study eye)
xPerforms fellow eye injection (if treatment is  administered bilaterally/in conjunction with 
study eye treatment)
xObserves safety at the end of the observati on period (approximately 30 minutes following 
study treatment)
xChecks IOP post-dose (study eye) before the end of the approximately 30-minute 
observation period
xChecks indirect ophthalmoscopy post-dose (study eye)
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 25
CONFIDENTIALAfter the week 24 and week 52 analyses, s tudy reports will be issued that will indicate the 
efficacy outcomes up to week 24 and week 52, respectively.  All patients and study personnel 
who were masked through week 24 and week 52 will remain masked to the individual patient 
treatment assignments e ven after the issuance of each study report, respectively.
5.5.2. Emergency Unmasking 
Unmasking of treatment assignment for a patient may be necessary due to a medical emergency 
or any other significant medical event (eg, pregnancy).
xIf unmasking is required:
Only the investigator will make the decision to unmask the treatment assignment.
Only the affected patient will be unmasked.
Unmasking of the treatment assignment mu st be performed via the IVRS; manual 
unmasking (ie, via the designated unmasked staff at the study site) will not be 
permitted
The investigator will notify Regeneron and/or designee before unmasking the patient, 
whenever possible
If emergency unmasking is required and the IVRS is not available, only the Regeneron Head of 
Pharmacovigilance and Risk Management or designee will un mask the patient and provide the 
treatment assignment to the investigator.
5.6. Treatment Logistics and Accountability
   
  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220319] be able to account for all opened and unopened study drug.  These records 
should contain the dates, quantity, and study medication
xdispensed to each patient,
xreturned from each pati ent (if applicable), and
xdisposed of at the site or returned to the sponsor or designee.
All accountability records must be made availabl e for inspection by [CONTACT_25008]; photocopi[INVESTIGATOR_24897].
Drug accountability will be also performed fo r aflibercept administered in the fellow eye.
5.6.4. Treatment Compliance
All drug compliance records must be kept curren t and must be made available for inspection by 
[CONTACT_28795].
5.7. Concomitant Medications and Procedures
Any treatment administered from the time of inf ormed consent to the final study visit will be 
considered concomitant medication.  This includes medications that were started before the study 
and are ongoing during the study.
If a pretreatment concomitant medication is admini stered in the study eye before injection (eg, 
antibiotic or anesthetic), it must be admini stered for both active and sham treatment.
5.7.1. Prohibited Medicati ons and Procedures 
Patients may not receive any medications (approved or investigational) for their diabetic 
retinopathy in the study eye other than the assign ed study treatment (aflibercept or sham) as 
specified in this protocol, unless they have developed PDR, ASNV, or DME (in which case they 
may be treated as indicated in section 5.2) or completed the end of study (week 100) visit 
assessments.  This includes medications administered  locally (eg, IVT, topi[INVESTIGATOR_2855], juxtascleral or 
periorbital routes), as well as those administered systemically, with the intent of treating the 
study and/or fellow eye.
Aflibercept will be provided for fellow eye use (see section 5.7.2 ); other anti-VEGF agents will 
not be allowed.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc . Page 27
CONFIDENTIAL5.7.2. Permitted Medications and Procedures
Fellow Eye
Intravitreal aflibercept (2 mg) will be made avai lable for patients who have CI-DME, PDR or 
ASNV in the fellow eye at study start (beginning  on day 1), or are diagnosed during the trial 
(refer to EYLEA USPI 2015 ).
Standard of care treatment (eg, PRP) will also be allowed for patients developi[INVESTIGATOR_873763].
The patient‚Äôs fellow eye may receive treatment on the same day a s  t h e  s t u d y  e y e  o r  a t  a n  
unscheduled visit.  All fellow eye treatments must be recorded on the electronic case report form 
(CRF) as a concomitant medication and/or procedure for  the fellow eye.  The fellow eye will not 
be considered an additional study eye.  Patients  who receive treatment for the fellow eye will not 
be required to be withdrawn from the study.  Sa fety of the fellow eye will be monitored and all 
AEs will be collected.  Other conditions in the fellow eye may be treated with approved 
therapi[INVESTIGATOR_014].
Any other medications that are considered necessary for the patient‚Äôs welfare, and that ar e not 
expected to interfere with the evaluation of the study drug, may be given at the discretion of the 
investigator.
6. STUDY SCHEDULE OF EVENTS AND VISIT DESCRIPTIONS
6.1. Schedule of Events
Study assessments and procedures are presented by [CONTACT_25010] 2 and Table 3 .
Additional details for the exploratory OC T-angiography sub-study are provided in Appendix 1 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 28
CONFIDENTIALTable 2: Schedule of Events ‚ÄìYear 1
Screening 
Visit 1Baseline 
Visit 2Year 1 Treatment Period
Study Procedure Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 111
Week -- 0 4 8 12 16 24 32 40 48 52
Day
(visit window)-21 to -1 129
¬± 7 days57
¬± 7 days85
¬± 7 days113
¬± 7 days169
¬± 7 days225
¬± 7 days281
¬± 7 days337
¬± 7 days365
¬± 10 days
Screening/Baseline:
Informed consent X
Inclusion/exclusion X X
Medical and ophthalmic history X
Demographics X
Randomization X
Treatment:
Review of concomitant medications X X X X X X X X X X X
Administer IVT aflibercept (IAI) or 
sham2 XXXXXXXXX
Ocular Assessments:
BCVA (ETDRS) and refraction X X X X X X X X X X X
Slit lamp examination X X X X X X X X X X X
Gonioscopy3X X X X X
Intraocular pressure4X X X X X X X X X X X
Indirect ophthalmoscopy5X X X X X X X X X X X
SD-OCT X X X X X X X X X X X
FA & FP6X X7X X X X
Visual field testing (study eye)8X9X
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 29
CONFIDENTIALScreening 
Visit 1Baseline 
Visit 2Year 1 Treatment Period
Study Procedure Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 111
Week -- 0 4 8 12 16 24 32 40 48 52
Day
(visit window)-21 to -1 129
¬± 7 days57
¬± 7 days85
¬± 7 days113
¬± 7 days169
¬± 7 days225
¬± 7 days281
¬± 7 days337
¬± 7 days365
¬± 10 days
Non-Ocular Assessments:
Physical examination X10
Vital signs11X X X X X X X X X X X
ECG X X
Adverse events12X X X X X X X X X X X
Laboratory Testing:[ADDRESS_1220320], women of 
childbearing potential16 serum urine urine urine urine urine urine urine urine urine
Anti-aflibercept antibody samples17X X
1.Patients who are withdrawn from the study before week 52/ visit 11 will be asked to r eturn to the clinic to complete the visit 11 assessments.
2.Patients will receive either IAI or sham injections given by [CONTACT_3433] e unmasked investigator, depending on the assigned treatment g roup.
3.Gonioscopy in the study eye only .
4.Intraocular pressure will be measured pre -dose (bilateral) and ap proximately 30 minutes after administration of study drug on days when study drug/sham is 
administered (study eye only).
5.Indirect ophthalmoscopy will be performed pre -dose (bilateral) and immediately after administration of study drug on days when study dr ug is administered 
(study eye only).
6.An FP must be performed once a patient has been diagnosed with PDR, ASNV, or CI-DME in the study eye, and before rescue treatment is given. For sites 
that will capture FA images on the Optos¬ÆUltra -Widefield Imaging sy stem, axial length must be measured in both eyes at baseline using any appropriate 
method .
7.Only FP at week 8.
8.Only sites that have access to Humphrey Visual Field will perform visual field testing at the indicated visits. 
9.May be performed at visit 1 or vi sit 2.
10.Including height and weight.
11.Vital signs (body temperature, blood pressure, and heart rate) will be measured after the patient has been sitting for 5 minu tes.
12.Adverse events will be collected from the time  the informed consent form (ICF) is signed until early termination or the end of study visit.  If a patient 
withdraws from the study, ongoing AEs will be followed to th e end of study visit or until the patient withdraws consent. 
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 30
CONFIDENTIAL13.All samples collected for laboratory assessments will be obtained pri or to administration of study drug.
14.At visits at which FA is performed, urinalysis samples will be collected before FA in order to avoid false elevations in urin e protein values. Vitamin D will 
be tested at visit 1 (screening) only.
15.Sampling only for HbA1 c.
16.For women of childbearing potential, a negati ve screening serum pregnancy test and ur ine pregnancy test on day [ADDRESS_1220321] at each treatment visit starting at visit 2 (day 1); a negative urine pregnancy test is required 
before treatment is administered (random ized treatment, rescue treatment with IAI, or fellow eye treatment with IAI).
17.All ADA samples must be collected prior to administration of study drug on d ays when study drug is administered.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 31
CONFIDENTIALTable 3: Schedule of Events ‚ÄìYear 2
Study Procedure Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 Visit 17Visit 18/End 
of Study1
Week 56 64 72 80 88 96 100
Day
(visit window)393
¬± 7 days449
¬± 7 days505
¬± 7 days561
¬±7 days617
¬± 7 days673
¬± 7 days701
¬± 10 days
Treatment:
Review of concomitant medications X X X X X X X
Administer IVT aflibercept (IAI) or sham2X X X X X X
Ocular Assessments:
BCVA (ETDRS) and refraction X X X X X X X
Slit lamp examination X X X X X X X
Gonioscopy3X X X
Intraocular pressure4X X X X X X X
Indirect ophthalmoscopy5X X X X X X X
SD-OCT X X X X X X X
FP6X X X X X X X
FA7X X X
Visual field testing (study eye)8X
Non-Ocular Assessments:
Vital signs9X X X X X X X
ECG X
Adverse events10X X X X X X X
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 32
CONFIDENTIALStudy Procedure Visit 12 Visit 13 Visit 14 Visit 15 Visit 16 Visit 17Visit 18/End 
of Study1
Week 56 64 72 80 88 96 100
Day
(visit window)393
¬± 7 days449
¬± 7 days505
¬± 7 days561
¬±7 days617
¬± 7 days673
¬± 7 days701
¬± 10 days
Laboratory Testing:[ADDRESS_1220322], women of childbearing 
potential13 urine urine urine urine urine urine urine
Anti-aflibercept antibody samples14X
1.Patients who are withdrawn from the study after week 52/visit 11  will be asked to return to the clinic for week 100/visit 18 assessments.
2.Patients will receive either IAI or sham injections given by [CONTACT_496156], depending on the assigned treatment group.
3.Gonioscopy in the study eye only .
4.Intraocular pressure will be measured pre -dose (bilateral) and approximately 30 minutes after administration of study d rug on days when study drug/sham is 
administered (study eye only).
5.Indirect ophthalmoscopy will be performed pre -dose (bilateral) and immediately after administration of stud y drug on days when study drug is administered 
(study eye only).
6.An FP must also b e performed once a patient has been diagnosed with PDR, ASNV, or CI-DME in the study eye, and before rescue treatment is given.
7.For sites that will capture FA images on the Optos¬ÆUltra -Widefield Imaging system, axial length must be measured in both eyes at baseline using any 
appropriate method .
8.Only sites that have access to Humphrey Visual Field will perform visual field testing at the indicated visits.
9.Vital signs (body temperature, blood pressure, and heart rate) will be measur ed after the patient has been sitting for 5 minutes.
10.Adverse events will be collected from the time the ICF is signed  until early termination or the end of study visit.  If a pat ient withdraws from the study, 
ongoing AEs will be followed to the end of study visit or until the pat ient withdraws consent.
11.All samples collected for laboratory assessments should be obtained prior to administration of study drug.
12.At visits at which FA is performed, urinalysis samples will be  collected before FA in order to  avoid false elevations in urin e protein values. Vitamin D will 
be tested at visit 18 (week 100) only.
13.All women of childbearing potential will have a urine pregnancy test at each treatment visit starting at visit 2 (day 1).  A negative urine pregnancy test is 
required before treatment is administered (randomized treatment, rescue trea tment with IAI, or fellow eye treatment with IAI)
14.All ADA samples must be collected prior to administration of study drug on days when study drug is administered.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 33
CONFIDENTIAL6.2. Study Visit Descriptions
6.2.1. Early Termination Visit
Patients who are withdrawn from the study before week 52/visit 11 will be asked to return to the 
clinic to complete the visit 11 assessments, as described in Table 2 . Patients who are withdrawn 
from the study after week 52/visit 11 will be asked to return to the clinic for week 100/visit 18 assessments, as described in Table 3 .
6.2.2. Unscheduled Visits
All attempts should be made to keep patients on the study schedule.  However, unscheduled 
visits may be necessary to evaluate or repeat tes ting following abnormal laboratory results, for 
follow-up of AEs, for rescue treatment for the stud y eye, for treatment of the fellow eye, or for 
any other reason, as warranted.
6.3. Study Procedures
6.3.1. Procedures Performed Only at the Screening/Baseline Visit
For women of childbearing potential, a negative se rum pregnancy test at screening is required for 
eligibility.
6.3.2. Ocular Procedures (Efficacy and Safety)
[IP_ADDRESS]. Best Corrected Visual Acuity 
Visual function of the study eye and the fellow eye will be assessed us ing the ETDRS protocol 
(The Early Treatment Diabetic Retinopathy Study Group 1985 ) at [ADDRESS_1220323] 
corrected visual acuity should be done before any other ocular procedures are performed.  A 
detailed protocol for conducting VA testing and re fraction can be found in the study procedure 
manual.
[IP_ADDRESS]. Intraocular Pressure
Intraocular pressure of the study eye will be mea sured at every visit using Goldmann applanation 
tonometry or Tono-pen‚Ñ¢, as specified in Table [ADDRESS_1220324] be used throughout the study for each individual patient.  Intraocular pressure 
will be measured pre-dose (bilateral) by [CONTACT_496160] (or designee), and at 
approximately [ADDRESS_1220325]-dose (study eye) by [CONTACT_496161] (or designee).
[IP_ADDRESS]. Slit Lamp Examination
Patients‚Äô anterior eye structure and ocular adnexa will be exam ined bil aterally pre-dose at each 
study visit using a slit lamp (study procedure manua l) by [CONTACT_286823], as specified in 
Table 2 and Table 3 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 34
CONFIDENTIAL6.3.2.4. Gonioscopy
Patients will be evaluated for the development of neovascularization of the iridocorneal angle by 
[CONTACT_873777]. The examination should be performed 
in the study eye only before the application of mydriatic agents, as specified in Table 2 and 
Table 3 , or if frank rubeosis is present.
[IP_ADDRESS]. Indirect Ophthalmoscopy 
Patients‚Äô posterior pole and peripheral retina will be examined  by [CONTACT_314899] a t
each study visit pre-dose (bilateral) by [CONTACT_496163]-dose (study eye) by [CONTACT_496164], as specified in Table [ADDRESS_1220326] be 
performed immediately after injection (active drug or sham).
[IP_ADDRESS]. Fundus Photography/Fluorescein Angiography
The anatomical state of the retinal vasculature and the DRSS level will be evaluated by [CONTACT_873778] [ADDRESS_1220327] be certified by [CONTACT_873779].  Ev ery effort will be made to ensure that all photographers at the 
site remain masked to treatment assignment.   A detailed protocol for image acquisition and 
transmission can be found in the study procedure manual.
For sites that will capture FA images on the Optos¬ÆUltra-Widefield Imaging system, axial 
length must be measured in both eyes at baseline using any appropriate method.
[IP_ADDRESS]. Spectral Domain Optical Coherence Tomography
Retinal characteristics will be evaluated at ever y visit using SD-OCT.  Images will be captured 
and transmitted for both eyes.  Images will be sent to an independent reading center where they will be read by [CONTACT_15467].  All OCTs will be electronically archived at the study sites as 
part of the source documentation.  Optical coherence tomography te chnicians must be certified 
by [CONTACT_873780].  Every effort will be 
made to ensure that OCT technicians at the study site remain masked to treatment assignment.  A 
detailed protocol for acceptable OCT machines a nd OCT image acquisition/ transmission can be 
found in the study procedure manual.
Details on an optional sub-study evaluating an exploratory OCT-angiography procedure are 
provided in Appendix 1 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220328] be certified to 
ensure consistency and quality testing procedures. Every effort will be made to ensure that visual 
field technicians at the study site remain maske d to treatment assignment. A detailed protocol 
for visual field testing can be found in the study procedure manual.
6.3.3. Safety Procedures (Non-Ocular)
[IP_ADDRESS]. Vital Signs
Vital signs, including body temperature, blood pressure, and heart rate will be collected pre-dose 
at time points according to Table 2 and Table 3 .  Vital sign measurements will be taken once the 
patient has been sitting down for 5 minutes.
[IP_ADDRESS]. Physical Examination
A physical examination, including height and weight, will be performed at the screening visit.
[IP_ADDRESS]. Electrocardiogram
A standard 12-lead ECG measurement will be measured at visits specified in Table 2 and 
Table 3 .  Heart rate will be recorded from the ventricular rate and the PR, QRS, RR and QT 
intervals will be recorded.  The ECG strips or report will be retained with the source 
documentation.  Electrocardiograms will be forwarded to a central reader.
[IP_ADDRESS]. Laboratory Testing 
Hematology, blood chemistry, urinalysis, HbA1c, and pregnancy testing samples will be 
analyzed by a central laboratory.  All samples collected for laboratory assessments will be 
obtained prior to administration of study drug.  At  visits at which FA is performed, urinalysis 
samples must be collected before FA to avoid fa lse elevations in urine protein values.  Detailed 
instructions for blood sample collection are in  the laboratory manual provided to study sites.
Samples for laboratory testing will be collected at time points according to Table 2 and Table 3 .  
Tests will include:
Blood Chemistry
Sodium Total protein, serum Total bilirubin
Potassium Creatinine Total cholesterol
Chloride Blood urea nitrogen (BUN) Uric acid
Carbon dioxide Aspartate aminotransferase (AST) Creatine phosphokinase (CPK)
Calcium Alanine aminotransferase (ALT)
Glucose Alkaline phosphatase
Albumin Lactate dehydrogenase (LDH)
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 36
CONFIDENTIALHematology
Hemoglobin Differential:
Hematocrit Neutrophils
Red blood cells (RBCs) Lymphocytes
White blood cells (WBCs) Monocytes
Red cell indices Basophils
Platelet count Eosinophils
Urinalysis
Color Urine protein:creatinine ratio RBC
Clarity Glucose Hyaline and other casts
Creatinine Blood Bacteria
pH Bilirubin Epi[INVESTIGATOR_873764] A1c and Vitamin D will be  measured at time points according to Table [ADDRESS_1220329] before 
randomization.  They should continue to be teste d for pregnancy (urine pregnancy test) during 
the study at every treatment visit.  For patients  on an IAI rescue regimen, or those being treated 
with IAI in the fellow eye, urine pregnancy test should be done before each dose.
Abnormal Laboratory Values and Laboratory Adverse Events
xAll laboratory values must be reviewed by [CONTACT_873781].
xSignificantly abnormal tests must be repea ted to confirm the nature and degree of the 
abnormality.  When necessary, appropriate ancillary investigations should be 
initiated.  If the abnormality fails to resolve or cannot be explained by [CONTACT_25037], the medical 
monitor must be consulted.
xThe clinical significance of an abnormal test value, within the context of the disease 
under study, must be determined by [CONTACT_286823].
Criteria for reporting laboratory values as an AE are provided in section 7.2.5 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe -OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 37
CONFIDENTIAL6.3.4. Anti -Drug Antibody Procedures
[IP_ADDRESS]. Anti-Drug Antibody Measurements and Samples
Samples for anti -drug antibody (ADA) assessment will be  collected at time points listed in 
Table 2and Table 3.  Samples should b e collected prior to the ad ministration of study drug.  
Samples collected for ADA measurements may be us ed for exploratory analysis or to investigate 
unexpected AEs.
  
7. SAFETY DEFINITIONS, REPORTING, AND MONIT ORING
7.1. Definitions
7.1.1. Adverse Event
An AE is any untoward medical occurrence in a patient administered a study drug which may or 
may not have a causal relationship with the study drug.  Therefore, an AE is a ny unfavorable and 
unintended sign (including abnormal labor atory finding), symptom, or disease which is 
temporally associated with the use of a study drug, whether or not considered related to the study 
drug.
An AE also includes any worsening (ie, any cli nically significant change in frequency and/or 
intensity) of a preexisting condition that is temporally associated with the use of the study drug.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220330] medical occurrence that at any dose:
xResults in death ‚Äìincludes all deaths, even those that appear to be completely 
unrelated to study drug (eg, a car accident in which a patient is a passenger).
xIs life-threatening ‚Äìin the view of the investigator, the patient is at immediate risk of 
death at the time of the event. This does not include an AE that had it occurred in a more severe form, might have caused death.
xRequires in-patient hospi[INVESTIGATOR_873765] .
In-patient hospi[INVESTIGATOR_24927] a hospi[INVESTIGATOR_73422] 24 hours.  Prolongation of existing hospi[INVESTIGATOR_31561] a 
hospi[INVESTIGATOR_24929], or is 
prolonged due to the development of a new AE as determined by [CONTACT_873782].
xResults in persistent or significant disability/incapacity (substantial disruption of 
one‚Äôs ability to conduct normal life functions).
xIs a congenital anomaly/birth defect
xIs an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_059], but may jeopardize the patient ormay require intervention to prevent 1 of the other serious outcomes listed above 
(eg, intensive treatment in an emergency room or at home for allergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development 
of drug dependency or drug abuse).
An ocular important medical event may include the following:
xAn AE that requires either surgical or medical intervention to prevent permanent loss 
of vision
xSubstantial, unexplained vision loss or an AE that causes substantial vision loss
7.2. Recording and Reporting Adverse Events
7.2.1. Adverse Events
The investigator (or designee) will record all AE s that occur from the time the informed consent 
is signed until the end of study.  Refer to the study procedure manual for the procedures to be 
followed.
Information on follow-up for AEs is provided in section 7.2.6 .  Laboratory, vital signs, or ECG 
abnormalities are to be recorded as AEs as outlined in section 7.2.5 .
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220331] be reported to the 
sponsor (or designee) within [ADDRESS_1220332] (IRB) all unanticipated 
problems involving risks to patients.  This include s death from any cause and all SAEs related to 
the use of the study drug.  It is recommended that all SAEs be reported to the IRB, regardless of 
assessed causality.
In the event the investigator is informed of an  SAE after the patient completes the study, the 
following will apply:
xSAE with an onset within 30 days of the end of study/early termination visit - the
SAE will be reported to the sponsor.  The investigator should make every effort to 
obtain follow-up information on the outcome until the event is considered chronic 
and/or stable.
xSAE with an onset day greater than 30 days from the end of study/early termination 
visit - only fatal SAEs and those deemed by [CONTACT_50460]-related SAEs will be reported to the sponsor.  The investigator should make every effort to obtain 
follow-up information on the outcome of a drug-related SAE until the event is 
considered chronic and/or stable.
7.2.3. Other Events that Require Accelerated Reporting
The following events also require reporting to the sponsor (or designee) within 24 hours of 
learning of the event:
Symptomatic Overdose of Study Drug: Accidental or intentional overdose of at least 
2 times the intended dose of study drug within the intended therapeutic window, if associated with an AE,
Pregnancy: Although pregnancy is not considered an AE, it is the responsibility of the 
investigator to report to the sponsor (or designee), by [CONTACT_16470] 
[ADDRESS_1220333] dose of study drug.  Any complication of  pregnancy affecting a female study 
patient or female partner of a male study patient, and/or fetus and/or newborn 
must be reported as an SAE.
Refer to the study procedure manual for the procedures to be followed.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 40
CONFIDENTIAL7.2.4. Reporting Adverse Events Leading to Withdrawal from the Study
All AEs that lead to a patient ‚Äôs withdrawal from the study must be reported to the sponsor‚Äôs 
medical monitor within [ADDRESS_1220334] finding should be reported as an 
AE include:
xthe test result is associated with accompanying symptoms, and/or
xthe test result requires additional diagnos tic testing or medical/surgical intervention, 
and/or
xthe test result leads to a change in dosing (outside of protocol-stipulated dose 
adjustments), discontinuation from the study, significant additional concomitant drug treatment, or other therapy
Contact [CONTACT_101881], although it  does not meet any of the above criteria.
Repeating an abnormal test, in th e absence of any of the above conditions, does not constitute an 
AE.  Any abnormal test result that is determined to be an error does not require reporting as an 
AE.
Evaluation of severity of laboratory abnormalitie s will be assessed according to the scale 
outlined in section 7.3.1 .
7.2.6. Follow-up
Adverse event information will be collected until the patient ‚Äôs last study visit.
Serious adverse event information will be collected  until the event is considered chronic and/or 
stable.
7.3. Evaluation of Severity and Causality
7.3.1. Evaluation of Severity
The severity of AEs will be graded according to the following scale:
xMild: Does not interfere in a significant manner with the patient ‚Äôs normal 
functioning level.  It may be an annoyance.  Prescription drugs are not ordinarily needed for relief of symptoms, but may be given because of personality of the patient.
xModerate: Produces some impairment of functioning but is not hazardous to health.  
It is uncomfortable or an embarrassment.   Treatment for symptom may be needed.
xSevere: Produces significant impairment of fu nctioning or incapacitation and is a 
definite hazard to the patient ‚Äôs health.  Treatment for symptom may be given and/or 
patient hospi[INVESTIGATOR_057].
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 41
CONFIDENTIAL7.3.2. Evaluation of Causality
Relationship of AEs to Study Drug:
The relationship of AEs to study drug will be a ssessed by [CONTACT_286823], and will be a 
clinical decision based on all available information.  The following question will be addressed:
Is there a reasonable possibility that the AE may have been caused by [CONTACT_5257]?The possible answers are:
Not Related: There is no reasonable possibility that the event may have been caused by 
[CONTACT_873783]: There is a reasonable possibility that the event may have been caused by 
[CONTACT_873784] a list of factors to consider in assessi ng the relationship of AEs to study drug, see 
Appendix [ADDRESS_1220335] information to justify th e causality assessment of SAEs, as needed.
Relationship of AEs to Injection Procedure:
The relationship of AEs to injection procedure will  be assessed by [CONTACT_286823], and 
will be a clinical decision based on all availa ble information.  The following question will be 
addressed:
Is there a reasonable possibility that the AE may have been caused by [CONTACT_104250]?
The possible answers are:
Not Related: There is no reasonable possibility that the event may have been caused by 
[CONTACT_873785]: There is a reasonable possibility that the event may have been caused by 
[CONTACT_873786] a list of factors to consider in assessing the relationship of AEs to the injection procedure, 
see Appendix [ADDRESS_1220336] information to justify th e causality assessment of SAEs, as needed.
7.4. Safety Monitoring
The investigator will monitor the safety of study pa tients at his/her site(s ) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP).  Any questions or 
concerns should be discussed with the sponsor in a timely fashion.  The sponsor will monitor the 
safety data from across all study sites.  The med ical monitor will have primary responsibility for 
the emerging safety profile of the compound.  The study monitor will be supported by [CONTACT_25047] (eg, Pharmacovigilance and Risk Management; Biostatistics and Data 
Management).  Safety monitoring will be perfor med on an ongoing basis (eg, individual review 
of SAEs) and on a periodic cu mulative aggregate basis.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 42
CONFIDENTIAL7.5. Investigator Alert Notification
Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as 
in any other clinical trial using the same investig ational drug, of any SAE that meets the relevant 
requirements for expedited reporting (an AE  that is serious, unexpected based on the 
Investigator‚Äôs Brochure, and has a reasonable suspected causal relationship to the 
medicinal/study drug).
8. STUDY VARIABLES
8.1. Demographic and Baseline Characteristics
Baseline characteristics will include standard de mography (eg, age, race, weight, height, etc), 
disease characteristics including medical hist ory, and medication history for each patient.
8.2. Primary and Secondary Variables
The primary outcome measure of the study is the proportion of patients who have improved by 
‚â•2steps from baseline in the DRSS score at week 24 in the combined 2Q8 and 2Q16 groups, and 
at week 52 for each group separately.
The secondary outcome measures will be tested at week 52 and are as follows:
xProportion of patients developi[INVESTIGATOR_007] a vision -threatening complication due to diabetic 
retinopathy
Vision-threatening complications are defined as composite outcome of PDR 
(inclusive of patients who have vitreous hemorrhage or tracti onal retinal detachment 
believed to be due to PDR) and ASNV
Note: ASNV is defined as neovascularization of  the iris (at least 2 cumulative 
clock hours), and/or definitive neovascu larization of the iridocorneal angle
xProportion of patients who develop CI-DME
xTime to development of a vision-threatening complication
xTime to development of CI-DME
xProportion of patients who receive PRP, inclu sive of patients undergoing vitrectomy 
with endolaser 
xArea under the curve (AUC) for change in BCVA from baseline
See section [IP_ADDRESS] for hierarchy of endpoints to be tested.  These outcome measures will also be 
tested at week 100 in an exploratory manner for all 3 treatment groups. 
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 43
CONFIDENTIAL8.3. Additional Variables
The additional outcome measures in the study are:
xTime to first improvement of ‚â•2 steps from baseline in t he DRSS score through week 52
and week 100
xProportion of patients with ‚â•2 -step improvement from baseline in the DRSS score at 
week 100
xProportion of patients with ‚â•2 -step worsening from baseline in the DRSS score at 
week 52 and at week 100
xProportion of patients with ‚â•3 -step worsening from baseline in the DRSS score at 
week 52 and at week 100
xProportion of patients with ‚â•[ADDRESS_1220337] ‚â•5, ‚â•10, or ‚â•15 letters from baseline at 
week 52 and at week 100
xThe proportion of patients who are equal to or better than 20/20 or equal to or better than 
20/40 at week 52 and at week 100
The following additional variables will be tested only at the week 24 time point:
xChange in BCVA from baseline at week [ADDRESS_1220338] ‚â•5, ‚â•10, or ‚â•15 letters fr om baseline at week 24
9. STATISTICAL PLAN
This section provides the basis for the SAP for th e study.  Analysis variables are listed in 
section 8.
9.1. Statistical Hypothesis
This study will examine the following hypotheses for the primary efficacy variable regarding the 
proportion of patients with a ‚â•2 -step improvement from baseline in  DRSS score in the study eye 
at week 24 in the combined 2Q8 and 2Q16 groups, and at week 52 for the 2Q8 and 2Q16 groups 
separately.  Statistical testing of week 24 and w eek 52 will be conducted  to demonstrate the 
superiority of the aflibercept groups (combined, 2Q8, and 2Q16) to the sham group, respectively.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220339], let p t(and p c) be the true proportion of patients with a ‚â•2 -step improvement from 
baseline in DRSS score at week 24 for the comb ined 2Q8 and 2Q16 groups, and at week 52 for 
the 2Q8 and 2Q16 groups separately (and the sham group, p c).
The following hypotheses will be tested:
H0: pt= p cversus H 1: pt‚â† p c
To control the family-wise type I error rate of 5%, primary efficacy endpoints for the combined 
group (week 24) and endpoints for the 2Q8 and 2Q16 groups (week 52) will be tested separately 
at the significance level of Œ± = 1.67% (5%/3 ).  Secondary efficacy endpoints at week 52 will be 
tested for the 2Q8 and 2Q16 groups by [CONTACT_873787] 4 .
Table 4: Significance Levels for Testing Secondary Efficacy Endpoints
Scenario 1234567
Combined Group at Week 
24 Positive?XXX X
2Q8 Group at Week 52 
Positive?XX X X
2Q16 Group at Week 52 
Positive?XX X X
Significan ce level 
forsecondary endpoints0.05 0.033 0.033 0.033 0.0167 0.0167
Significan ce level for 
Testing for 2Q8 Group at 
week 520.025 0.033 0.0167 0.0167
Significan ce level for 
Testing for 2Q16 at week 520.025 0.033 0.0167 0.0167
9.2. Justification of Sample Size
Anticipating approximately 41% of patients with a ‚â•2 -step improvement from baseline in DRSS 
score in either the 2Q8 or 2Q16 groups versus 17%  in the sham group, [ADDRESS_1220340] a difference with a power of 90% for rejecting the null hypothesis at a 2-sided 
1.67% (5%/3) significance level.  A sample size of [ADDRESS_1220341] 
90% power to detect a difference between th e combined aflibercept group and sham group at 
week 24, if a 38% response rate is assumed in the combined aflibercept group. The assumption 
of the proportions for the aflibercept group and sham group is based on VIVID and VISTA data 
at a given time point.  To account for about a 15% dropout rate, [ADDRESS_1220342] (continuity corrected) from 
the commercial software nQuery nTerm 7.0.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 45
CONFIDENTIAL9.3. Analysis Sets
9.3.1. Efficacy Analysis Sets
Full analysis set (FAS):  The FAS will include all randomized patients who received any study 
treatment.  The analysis on the FAS will be performed according to the treatment assigned at 
baseline (as randomized).
9.3.2. Safety Analysis Set
The safety analysis set (SAF) includes all random ized patients who received any study treatment 
(active or sham); it is based on the randomized treatment.  Treatment compliance/administration 
and all clinical safety variables will be analyzed using the SAF.
9.4. Patient Disposition
The following will be provided:
xThe total number of screened patients:  met the inclusion criteria regarding the target 
indication and signed the ICF
xThe total number of randomized patients:  received a randomization number
xThe total number of patients in each analysis set
xThe total number of patients who discontinued the study, and the reasons for 
discontinuation
xA listing of patients treated but not random ized, patients randomized but not treated, 
and patients randomized but not treated as randomized
xA listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation
9.5. Statistical Methods
The statistical methods summarized in this section out line the plan for data analysis of this study.  
A final and complete SAP will be provided prior to the unmasking of the data.
Unless stated otherwise, all variables will be an alyzed descriptively with appropriate statistical 
methods:  continuous variables by [CONTACT_873788] (ie, mean, standard deviation, median, 
quartiles, minimum, and maximum), and categorical  variables by [CONTACT_22977].
All statistical analyses will be performed usin g Statistical Analysis System (SAS); the version 
used will be specified in the SAP.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 46
CONFIDENTIAL9.5.1. Demography and Baseline Characteristics
Demographic variables and baseline  characteristics will be summarized by [CONTACT_873789] a nd SAF, depending on the type of data, as 
described in section 9.5.  Medical history will be coded by  [CONTACT_12513] (MedDRA¬Æ) codes, and prior and c oncomitant medications by [CONTACT_107623] (ATC) codes (World Health Organization Drug Dictionary).  No formal comparison 
between treatment groups will be conducted.
Demographic and baseline characteristics will be  summarized descriptively by [CONTACT_1570].
9.5.2. Efficacy Analyses
Efficacy analyses of all efficacy variables defined in section 8.2will be conducted using the FAS 
population.  Missing values will be imputed with post-baseline values during the ontreatment 
period by [CONTACT_873790] (LOCF) procedure. For any patient who 
receives rescue treatment, measurements after resc ue is given will be imputed using the last 
observation prior to rescue treatment.
The primary endpoint analysis for the study will  be conducted at 2 time points (week 24 for the 
combined 2Q8 and 2Q16 groups, and week 52 for the 2Q8 and 2Q16 groups separately).  Each 
of the primary efficacy analyses will be tested at the 1.67% (5%/3) significance level to control 
for multiplicity.
The secondary endpoints described in section 8.2for both groups (2Q8 and 2Q16) will be tested 
in a hierarchical manner at week 52, as described in section 9.1.
Primary Efficacy Analysis for the Combined 2Q8 and 2Q16 Groups at Week 24 
This analysis will be conducted on the FAS and will include the primary efficacy endpoint at 
week 24 for the combined 2Q8 and 2Q16 groups only.
Primary Efficacy Analysis for the 2Q8 and 2Q16 Groups at Week 52 
This analysis will be conducted on the FAS and will include the primary efficacy endpoint at 
week 52 for the 2Q8 and 2Q16 groups separately.
[IP_ADDRESS]. Analyses of Primary and Secondary Efficacy Variables
Primary Efficacy Variable
The primary efficacy variable analysis will  be conducted on the FAS population. The primary 
analysis is a statistical evaluati on of superiority of 3 comparisons (combined aflibercept vs. sham 
at week 24, aflibercept 2Q8 vs. sham at week 52, and aflibercept 2Q16 vs. sham at week 52) in 
respect to the primary efficacy variable (see section 8.2). The statistical analysis will be 
performed using the Cochran-Mantel-Haenszel method, stratified by [CONTACT_873768] (level 
47 vs. level 53). Missing or nongradable post-baseline  values will be imputed using the LOCF 
procedure. For any patient who receives rescue treatment, the measurements after rescue is 
given will be imputed using the last observation pri or to rescue treatment. Baseline values will 
be carried forward if all post-baseline observations are missing or nongradable.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 47
CONFIDENTIALAflibercept treatment will be cons idered to be superior to sham if the estimated aflibercept group
(combined, aflibercept 2Q8, or aflibercept 2Q16) is greater than the sham group, and the p-value 
is less than or equal to or statistically significant at a 1.67% level.
As stated above, for the primary efficacy analysis, any patient who receives rescue treatment in 
the study eye will have all efficacy measurements  collected after rescue treatment is imputed 
using the last observation prior to such treatment. For a sensitivity analysis, the primary efficacy analysis will also be performed using all obs erved measurements (regardless of whether rescue 
treatment was given), and only true missing valu es will be imputed using the LOCF procedure. 
Baseline values will be carried forward if all post-baseline observations are missing or 
nongradable.
Secondary Efficacy Variables
If at least one of the aflibercept groups is shown to  be superior to sham in the primary variable, 
additional comparisons will be made for this af libercept group with resp ect to the secondary 
variables at week 52, using the significance level specified in section 9.1.
A hierarchical testing procedure will be performed for each dose group to compare the secondary 
variables between the respective aflibercept group and sham in the following order:
x2Q8 secondary endpoints at week 52
Proportion of patients developi[INVESTIGATOR_007] a vi sion-threatening complication due to 
diabetic retinopathy
Proportion of patients who develop CI-DME
Time to development of a vision-threatening complication
Time to development of CI-DME
Proportion of patients who receive PRP,  inclusive of patients undergoing 
vitrectomy with endolaser 
AUC for change in BCVA from baseline
x2Q16 secondary endpoints at week 52
Proportion of patients developi[INVESTIGATOR_007] a vi sion-threatening complication due to 
diabetic retinopathy
Proportion of patients who develop CI-DME
Time to development of a vision-threatening complication
Time to development of CI-DME
Proportion of patients who receive PRP,  inclusive of patients undergoing 
vitrectomy with endolaser 
AUC for change in BCVA from baseline
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 48
CONFIDENTIALThe p-values at week 52 for the secondary endpoints will be reported for all comparisons 
between the aflibercept groups and the sham group; however, a superiority claim can be made 
for a given endpoint only if all preceding endpoint comparisons in the hierarchy are shown to be 
statistically significant at a significance level specified in section 9.1. The hierarchical method 
ensures the overall type I error rate of 5% for this study, with multiplicity adjustment for primary 
and secondary endpoint analyses.
All endpoints will also be analyzed descriptively at week 100 in an exploratory manner. 
The analysis of proportion variables will be done using the same methodology as for the analyses 
of the primary efficacy variable described in this section.
For continuous variables (ie, BCVA), an analysis  of covariance (ANCOVA) model with baseline 
measurements of the continuous variable as covari ates and treatment and baseline DRSS score 
(level 47 vs. level 53) stratification as fixed fact ors will be used for the endpoint. The pair-wise 
comparisons of each aflibercept group versus sh am will be done in the ANCOVA model. In 
addition, 2-sided 95% confidence in tervals for the difference of each aflibercept group minus 
sham will be calculated.
Time to first vision-threatening co mplication (composite of PDR [inclu sive of patients who have 
vitreous hemorrhage or tractiona l retinal detachment believed to  be due to PDR] and ASNV) will 
be analyzed using the Kaplan-Meier estimates. A log-rank test will be performed, comparing 
sham with the aflibercept groups, as well as 2-si ded 95% confidence intervals for the time to first 
vision-threatening complication for the di fference of each comparison group. Time to 
development of CI-DME will be analyzed similarly.
Similar to the analysis of the primary endpoint, any patient who receives rescue treatment in the 
study eye will have all efficacy measurements co llected after rescue treatment imputed using the 
last observation prior to such treatment.  For a se nsitivity analysis, the primary efficacy analysis 
will also be performed using all observed measur ements (regardless of whether rescue treatment 
was given) and only true missing values will be imputed using the LOCF procedure.  Baseline
values will be carried forward if all post-baseline observations are missing.
Analyses of the primary and secondary endpoints may also be performed on subsets of the FAS, 
such as patients who have developed CI-DME, PDR, or patients who have had a vitrectomy.  
Such subsets will be defined in the SAP.
[IP_ADDRESS]. Analyses of Additional Efficacy Variables
All additional efficacy variables (see section 8.3) will be analyzed descriptively.  In addition, the 
primary and secondary variables will be also analyzed descriptively at week 100.  These 
descriptive analyses may include statistical tests on the proportion for the efficacy variables, in 
the same way as described for the primary and secondary efficacy variable analyses (see section [IP_ADDRESS] ).
The analysis of categorical variables will be  done using the same methodology used for the 
analysis of the primary efficacy variable described in section [IP_ADDRESS] . Analyses of continuous 
variables (eg, central retina l thickness, median deviation on visual field) will use a 2-way 
ANCOVA main effects models with treatment gr oup and baseline DRSS (level 47 vs. level 53) 
stratification as fixed factors and baseline a ssessment of the efficacy outcome measure as a 
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220343]  statements and a point-estimate.  A 2-sided
95% confidence interval for the treatment difference of each aflibercept treatment group minus 
sham will be calculated.
9.5.3. Safety Analysis
Safety variables will be summarized on the SAF through week 24 for the combined 2Q8 and 
2Q16 group, and the sham group.  Safety data  accumulated through week 52 and week 100 for 
each treatment group will be summarized at the respective time point.
[IP_ADDRESS]. Adverse Events
Definitions
For safety variables, 3 observation periods are defined:
xThe pretreatment period is defined as the time from signing the ICF to before the first 
dose of study drug.
xThe treatment period is defined as the day from first dose of study drug to the last 
dose of study drug.
xThe post-treatment period is defined as the time after the last dose of study drug 
A TEAE is defined as an event (or an exacerba tion of a preexisting event during the treatment 
period) that is observed or reported after the fi rst administration of study drug, and no later than 
[ADDRESS_1220344] administration of study drug (active or sham injection).
Analysis
All AEs reported in this study will be code d using the currently available version of the 
MedDRA.  Coding will be to lowest level terms.  The verbatim text, the preferred term (PT), and 
the primary system organ class (SOC) will be listed.
Summaries of all TEAEs by [CONTACT_1570], and by [CONTACT_801533], ocular fellow eye, and 
non-ocular TEAEs, will include:
xThe number (n) and percentage (%) of patients with at least 1 TEAE by [CONTACT_873791] (according to the grading scale outlined in section 7.3.1 ),
presented by [CONTACT_873792] (related, not related), presented 
by [CONTACT_873793].
Treatment-emergent adverse events leading to perm anent treatment disconti nuation will be listed 
and summarized by [CONTACT_1570].
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 50
CONFIDENTIAL9.5.3.2. Ocular Safety
Ocular safety variables (eg, IOP measurements) will  be analyzed descriptively at their scheduled 
visit, including changes from baseline.  All ocu lar safety parameters will be summarized using 
descriptive statistics.  Information from OCT, FP, and FA may also be used to assess ocular 
safety.
[IP_ADDRESS]. Other Safety
Vital Signs
Vital signs (body temperature, blood pressure, and hear t rate) will be summarized by [CONTACT_873794].
Laboratory Tests
Laboratory test results will be summarized by  [CONTACT_161479].
Number and percentage of patients with a potenti ally clinically significant value (PCSV) at any 
post-randomization time point will be summarized for each clinical laboratory test. 
Shift tables based on baseline normal/abnormal a nd other tabular and graphical methods may be 
used to present the results for laboratory tests of interest.
Listings will be provided with flags indicating the out of laboratory range values.
[IP_ADDRESS]. Treatment Exposure
Exposure to study drug will be examined for each patient.  The total number of treatments 
administered to each patient and the duration of treatment will be analyzed and summarized 
using descriptive statistics by [CONTACT_801536].
[IP_ADDRESS]. Treatment Compliance
Compliance with protocol-defined study medication will be calculated as follows:
Treatment compliance = (number of received injections [active or sham] through a given 
week)/(number of planned injections [active or  sham] during the period of participation in the 
study through the given week) x 100%.
The 24-week treatment period is defined as the pe riod from day 1 to week 16 (visit 6; last study 
treatment visit) plus 28 days.  For all treatmen t groups, the 52-week treatment period is defined 
as the period from day 1 to week 48 (visit 10/ last study treatment visit), and the 100-week 
treatment period is defined as the period from day 1 to week 96 (visit 17/last study treatment 
visit) plus 28 days. Sham injections will be counted as planned treatment.
9.6. Interim Analysis
No formal interim analysis is planned.  
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 51
CONFIDENTIAL9.7. Additional Statistical Data Handling Conventions
The following analysis and data conventions will be followed:
Definition of baseline: 
xThe baseline assessment is defined as  the latest valid pre-dose assessment
General rules for handling missing data:
xRules for handling missing data for efficacy assessments will use LOCF for patients in 
analysis populations as described.  Additional details will be provided in the SAP.
xIf the start date of an AE or concomitant medic ation is incomplete or missing, it will be 
assumed to have occurred on or after the intake of study medication, except if an 
incomplete date (eg, month and year) clearly indicates that the event started prior to 
treatment.  If the partial date indicates the same month or year of the intake of study 
medication date, then the start date by [CONTACT_197521]; 
otherwise, the missing day or month by [CONTACT_197522]. 
xNo imputations for missing laboratory data, ECG data, vital sign data, or physical 
examination data will be made.
Visit windows:
xAssessments taken outside of protocol allowable windows will be displayed according to 
the CRF assessment recorded by [CONTACT_093].
Unscheduled assessments:
xExtra assessments (laboratory data or vital signs associated with nonprotocol clinical 
visits or obtained in the course of investigating or managing AEs) will be included in 
listings, but not summaries.  If more than [ADDRESS_1220345] observation will be used in summaries and all observations will be presented in listings.
9.8. Statistical Considerations Surrounding the Premature Termination 
of a Study
If the study is terminated prematurely, only t hose parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and sponsor responsibilities surrounding the premature termination of a study are presented in section 15.1.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 52
CONFIDENTIAL10. DATA MANAGEMENT AND ELECTRONIC SYSTEMS
10.1. Data Management 
A data management plan specifying all relevant aspects of data processing for the study 
(including data validation, cleaning, correcting , releasing) will be maintained and stored at 
Regeneron.
A medical coding plan will specify the processe s and the dictionary used for coding.  All data 
coding (eg, AEs, baseline findings, medicati on, medical history/surgical history/ophthalmic 
history) will be done using internationally recognized and accepted dictionaries.
The CRF data for this study will be collected with an electronic data capture (EDC) tool, 
Medidata RAVE.
10.2. Electronic Systems
Electronic systems that may be used to process and/or collect data in this study will include the 
following:
xIVRS/IWRS system ‚Äìrandomization, study drug supply
xEDC system ‚Äìdata capture
xSAS ‚Äìstatistical review and analysis
xArgus ‚Äìa pharmacovigilance and clinical safety software system
11. STUDY MONITORING
11.1. Monitoring of Study Sites
The study monitor and/or designee (eg, contract  research organization monitor) will visit each 
site prior to enrollment of the fi rst patient, and periodically during the study.  In accordance with 
ICH guidelines, the monitor will compare the CRF entries with the appropriate source documents.  Additional review may include, but is  not limited to, patient ICFs, documentation of 
patient recruitment and follow-up, AEs, SAEs, and concomitant therapy; as well as records of 
study drug dispensing, compliance, and accountability.  A copy of the drug dispensing log must be provided to the sponsor upon request.
11.2. Source Document Requirements
Investigators are required to prepare and maintain adequate and accurate patient records (source documents).
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an el ectronic CRF).  Case report forms and source 
documents must be available at all times for inspection by [CONTACT_31609].
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220346] to a quality assura nce audit or inspection by [CONTACT_25063].  Should this occur, the investigator is responsible for:
xInforming the sponsor of a planned inspection by [CONTACT_31613], and authorizing the sponsor‚Äôs partici pation in the inspection
xProviding access to all necessary facilities, study data, and documents for the 
inspection or audit
xCommunicating any information arising from inspection by [CONTACT_873795], 
CRFs, medical records, correspondence, ICFs, IR B files, documentation of certification and 
quality control of supporting laboratories, and rec ords relevant to the study maintained in any 
supporting pharmacy facilities.  Conditions of study material storage are also subject to 
inspection.  In addition, representatives of the sponsor may observe the conduct of any aspect of 
the clinical study or its supporting activities bot h within and outside of the investigator's 
institution.
In all instances, the confidentiality of the data must be respected.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 54
CONFIDENTIAL13. ETHICAL AND REGULATORY CONSIDERATIONS
13.1. Good Clinical Practice Statement
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethi cal principles that have their origin in the 
Declaration of Helsinki, and that are consistent wi th the ICH guidelines for GCP and applicable 
regulatory requirements.
13.2. Informed Consent
The principles of informed consent are described in ICH guidelines for GCP.
The ICF used by [CONTACT_873796].  A copy of the IRB-approved ICF and documentation of 
approval must be provided to the sponsor before st udy drug will be shipped to the study site.
It is the responsibility of the investigator or designee (if acceptable by [CONTACT_427]) to obtain 
written informed consent from each patient prior to his/her participation in the study and after the 
aims, methods, objectives, and potential hazards of th e study have been explained to the patient
in language that he/she can understand.  The ICF s hould be signed and dated by [CONTACT_873797].
xPatients who can write but cannot read will have the ICF read to them before signing 
and dating the ICF.
xPatients who can understand but who can neit her write nor read will have the ICF 
read to them in presence of an impartial witness, who will sign and date the ICF toconfirm that informed consent was given.
The original ICF must be retained by [CONTACT_31616]'s study record, and a 
copy of the signed ICF must be given to the patient.
If new safety information results in significant changes in the risk/benefit assessment, the ICF 
must be reviewed and updated appropriately.  Al l study patients must be informed of the new 
information and provide their written c onsent if they wish to continue in the study.  The original 
signed revised ICF must be maintained in the patient ‚Äôs study record and a copy must be given to 
the patient.
13.3. Patient Confidentiality and Data Protection
The investigator must take all appropriate measures to ensure that the anonymity of each study patient will be maintained.  Patients should be  identified by [CONTACT_56706] a patient
identification number, only, on CRFs or other documents submitted to the sponsor.  Documents 
that will not be submitted to the sponsor (eg, signed ICF) must be kept in strict confidence.
The patient's and investigator's personal data, which may be included in the sponsor database, 
will be treated in compliance with all applicable laws and regulations.  The sponsor shall take all 
appropriate measures to safeguard and prevent acc ess to this data by [CONTACT_101896].
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220347] review and 
approve:
xThe protocol, ICF, and any other materials to be provided to the patients
(eg, advertising) before any patient may be enrolled in the study
xAny amendment or modification to the study protocol or ICF before implementation, 
unless the change is necessary to eliminate an immediate hazard to the patients, in which case the IRB should be informed as soon as possible
xOngoing studies on an annual basis or at intervals appropriate to the degree of risk
In addition, the IRB should be informed of any event li kely to affect the safety of patients or the 
continued conduct of the clinical study.
A copy of the IRB approval letter with a curren t list of the IRB members and their functions 
must be received by [CONTACT_873798].  The 
approval letter should include the study number and title, the documents reviewed, and the date
of the review.
Records of the IRB review and approval of all st udy documents (including approval of ongoing 
studies) must be kept on file by [CONTACT_093].
14. PROTOCOL AMENDMENTS
The sponsor may not implement a change in the design or operation of the protocol or ICF 
without an IRB-approved amendment.
15. PREMATURE TERMINATION OF THE STUDY OR 
CLOSE-OUT OF A SITE
15.1. Premature Termination of the Study
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor decide to terminate the study, the 
investigator(s) will be notified in writing.
15.2. Close-out of a Site
The sponsor and the investigator have the right to close-out a site prematurely.
Investigator‚Äôs Decision
The investigator must notify the sponsor of a desire  to close-out a site in writing, providing at 
least 30 days‚Äô notice.  The final decision should be made throu gh mutual agreement with the 
sponsor.  Both parties will arrange the close-out procedures after review and consultation.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 56
CONFIDENTIALSponsor‚Äôs Decision
The sponsor will notify the investigator(s) of a deci sion to close-out a study site in writing.  
Reasons may include the following, among others: 
xThe investigator has received all items and information necessary to perform the 
study, but has not enrolled any patient within a reasonable period of time
xThe investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or breach of any applicable ICH 
guidelines 
xThe total number of patients required for th e study are enrolled earlier than expected
In all cases, the appropriate IRB and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate c onsideration must be given to the protection 
of the patient s‚Äô interests.
16. STUDY DOCUMENTATION
16.1. Certification of Accuracy of Data
A declaration assuring the accuracy and content of the data recorded on th e CRFs must be signed 
by [CONTACT_093].  This certification form accomp anies each set of CRFs.  The signed form will 
be provided to the sponsor with the final set of CRFs for each patient.
16.2. Retention of Records
The investigator must retain all essential study documents, including ICFs, source documents, investigator copi[INVESTIGATOR_3110], and drug accountability records for at least [ADDRESS_1220348] be destroyed in a ma nner that ensures confidentiality.
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor and the relevan t records will be transferred to a mutually 
agreed-upon destination.
17. CONFIDENTIALITY
Confidentiality of information is  provided as a separate agreement.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 57
CONFIDENTIAL18. FINANCING AND INSURANCE
Financing and insurance information is provided as a separate agreement.
19. PUBLICATION POLICY
The publication policy is provided as a separate agreement.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 58
CONFIDENTIAL20. REFERENCES
Antithrombotic Trialists‚Äô Collaboration. Collaborativ e overview of randomized trial of 
antiplatelet therapy ‚ÄìII: Maintenance of vascular  graft or arterial patency by [CONTACT_873799].  
Br Med J 1994; 308:168-171.
Antithrombotic Trialists‚Äô Collaboration. Collaborative meta -analysis of randomised trials of
antiplatelet therapy for prevention of death, myoc ardial infarction, and stroke in high risk 
patients. Br Med J 2002; 324:71-86.
Bressler, NM, Beck RW, and Ferris FL, 3rd, Panretinal photocoagulation for proliferative 
diabetic retinopathy. The New England journal of medicine, 2011. 365(16):  1520-6.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al; RIDE and RISE 
Research Group.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 
36-month results from two phase III trials : RISE and RIDE.  Ophthalmology. [ADDRESS_1220349];120(10):2013-22.
Early Treatment Diabetic Retinopathy Study re search group.  Photocoagulation for diabetic 
macular edema. Early Treatment  Diabetic Retinopathy Study re port number 1. Arch Ophthalmol. 
1985 Dec;103(12):1796-806.
EYLEA¬Æ(aflibercept) Injection, [LOCATION_002] Prescribing Information, Revised July 2015.
Korobelnik, J. F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., et al. 
(2014). Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121, 2247-54
Wild S, Roglic G, Green A, Sicree R, King H.   Global prevalence of d iabetes: estimates for the 
year 2000 and projections for 2030.  Diabetes Care. 2004 May;27(5):1047-53.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 59
CONFIDENTIAL21. INVESTIGATOR‚ÄôS AGREE MENT
I have read the attached protocol:  A Phas e 3, Double-Masked, Randomized Study of the 
Efficacy and Safety of Intravitreal Aflibercept In jection in Patients with Moderately Severe to 
Severe Nonproliferative Diabetic Retinopathy, and agree to abide by [CONTACT_53398].
I agree to comply with the current Internati onal Conference on Harmonisation Guideline for 
Good Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, or locality relating to the conduct of the clinical study.
I also agree that persons debarred from conducti ng or working on clinical studies by [CONTACT_50487] a 
partnership in which the sponsor is involved.  I w ill immediately disclose it in writing to the 
sponsor if any person who is involved in the study is debarred, or if any proceeding for 
debarment is pending, or, to the best of my knowledge, threatened.
This document contains confident ial information of the sponsor, which must not be disclosed to 
anyone other than the recipi[INVESTIGATOR_873766].  I agree to ensure that this 
information will not be used for any purpose othe r than the evaluation or conduct of the clinical 
investigation without the prior written consent of the sponsor.
(Signature [CONTACT_7919]) (Date)
(Printed Name)
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220350] imaging.
B. Number of Patients and Sites
Patients will be enrolled at the inv estigator‚Äôs discretion at sites  that have access to the Optovue 
Angio-vue system.  There will be no cap on the number of patients or sites that may participate.
C. Timing of OCT-Angiography
Optical coherence tomography-angiography will be performed approximately quarterly at the 
time points indicated in Table 1 and Table 2, in conjunction with the scheduled study visits for 
the main study.
Table 1: Schedule of Events (OCT-Angiography) ‚ÄìYear 1
Screening 
Visit 1Year 1 Treatment Period
Study Procedure Visit 5 Visit 7 Visit 9 Visit 11
Week -- 12 24 40 52
Day
(visit window)-21 to -185
¬± 7 days169
¬± 7 days281
¬± 7 days365
¬± 10 
days
Signed Informed Consent X
Optical Coherence Tomography - Angiography X X X X X
Table 2: Schedule of Events (OCT-Angiography) ‚ÄìYear 2
Study Procedure Visit 13 Visit 15Visit 18/End 
of Study
Week 64 80 100
Day
(visit window)449
¬± 7 days561
¬± 7 days701
¬± 10 days
Optical Coherence Tomography - Angiography X X X
Detailed instructions for image collection and transmission will be provided in the study 
procedure manual.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-[ADDRESS_1220351] been caused by [CONTACT_873800]?
No:
xdue to external causes such as environmen tal factors or other treatment(s) being 
administered
xdue to the patient‚Äôs diseas e state or clinical condition
xdo not follow a reasonable temporal sequen ce following the time of administration of 
the dose of study drug or injection procedure
xdo not reappear or worsen when dosing with study drug or injection procedure is 
resumed
xare not a known response to the study drug or injection procedure based upon 
preclinical data or prior clinical data
Yes:
xcould not be explained by [CONTACT_28854](s) being 
administered
xcould not be explained by [CONTACT_180186]‚Äôs disease state or clinic al condition
xfollow a reasonable temporal sequence followi ng the time of administration of the 
dose of study drug or injection procedure
xresolve or improve after discontinuation of study drug or injection procedure
xreappear or worsen when dosing with study drug or injection procedure is resumed
xare known to be a response to the study drug or injection procedure based upon 
preclinical data or prior clinical data
NOTE: This list is not exhaustive.
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
Clinical Study Protocol VGFTe-OD-1411 Amendment 5
Regeneron Pharmaceuticals, Inc. Page 62
CONFIDENTIALSIGNATURE [CONTACT_11715] ‚ÄôS RESPONSIBLE OFFIC ERS
(Scientific/Medical Monitor, Regulatory Repres entative, Clinical Study Team Lead, and 
Biostatistician)
To the best of my knowledge, this report accu rately describes the conduct of the study and the 
data generated.
Study Title: A Phase 3, Double-Masked, Randomiz ed Study of the Efficacy and Safety of
Intravitreal Aflibercept Injection in Pati ents with Moderately Severe to Severe 
Nonproliferative Diabetic Retinopathy
Protocol Number: VGFTe-OD-1411
Protocol Version: VGFTe-OD-1411 Amendment 5
See appended electronic signature [CONTACT_873801]‚Äôs Responsible Scie ntific/Medical Monitor
See appended electronic signature [CONTACT_873801]‚Äôs Responsible Regulatory Representative
See appended electronic signature [CONTACT_873801]‚Äôs Responsible Clinical Study Team Lead
See appended electronic signature [CONTACT_873801]‚Äôs Responsible Biostatistician
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07
6LJQDWXUH3DJHIRU995,0Y
6LJQDWXUH3DJHIRU995,0Y$SSURYHG$SSURYDO
-XO*07
$SSURYDO
JHPHQW
-XO*07
$SSURYDO
-XO*07
$SSURYDO
-XO*07
995,0$SS URYHG-XO*07 995,0$SS URYHG-XO*07